0001517681 false --06-30 2021 FY 5 5 1 3 1 200000 0001517681 2020-07-01 2021-06-30 0001517681 2020-12-31 0001517681 2021-09-24 0001517681 2021-06-30 0001517681 2020-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2020-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2021-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2020-06-30 0001517681 2019-07-01 2020-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2019-06-30 0001517681 us-gaap:CommonStockMember 2019-06-30 0001517681 PPCB:CommonStockIssuableMember 2019-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001517681 us-gaap:RetainedEarningsMember 2019-06-30 0001517681 PPCB:AccumulatedOtherComprehensiveIncomeLossMember 2019-06-30 0001517681 us-gaap:TreasuryStockMember 2019-06-30 0001517681 2019-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2019-07-01 2020-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2019-07-01 2020-06-30 0001517681 us-gaap:CommonStockMember 2019-07-01 2020-06-30 0001517681 PPCB:CommonStockIssuableMember 2019-07-01 2020-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-06-30 0001517681 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0001517681 PPCB:AccumulatedOtherComprehensiveIncomeLossMember 2019-07-01 2020-06-30 0001517681 us-gaap:TreasuryStockMember 2019-07-01 2020-06-30 0001517681 us-gaap:CommonStockMember 2020-06-30 0001517681 PPCB:CommonStockIssuableMember 2020-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001517681 us-gaap:RetainedEarningsMember 2020-06-30 0001517681 PPCB:AccumulatedOtherComprehensiveIncomeLossMember 2020-06-30 0001517681 us-gaap:TreasuryStockMember 2020-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2020-07-01 2021-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2020-07-01 2021-06-30 0001517681 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0001517681 PPCB:CommonStockIssuableMember 2020-07-01 2021-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0001517681 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0001517681 PPCB:AccumulatedOtherComprehensiveIncomeLossMember 2020-07-01 2021-06-30 0001517681 us-gaap:TreasuryStockMember 2020-07-01 2021-06-30 0001517681 us-gaap:CommonStockMember 2021-06-30 0001517681 PPCB:CommonStockIssuableMember 2021-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001517681 us-gaap:RetainedEarningsMember 2021-06-30 0001517681 PPCB:AccumulatedOtherComprehensiveIncomeLossMember 2021-06-30 0001517681 us-gaap:TreasuryStockMember 2021-06-30 0001517681 2020-11-16 2020-11-17 0001517681 PPCB:IntercompanyLoansMember 2020-07-01 2021-06-30 0001517681 PPCB:IntercompanyLoansMember 2019-07-01 2020-06-30 0001517681 srt:WeightedAverageMember 2021-06-30 0001517681 srt:WeightedAverageMember 2020-06-30 0001517681 us-gaap:MachineryAndEquipmentMember 2020-07-01 2021-06-30 0001517681 us-gaap:FurnitureAndFixturesMember 2020-07-01 2021-06-30 0001517681 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0001517681 us-gaap:EmployeeStockOptionMember 2019-07-01 2020-06-30 0001517681 us-gaap:WarrantMember 2020-07-01 2021-06-30 0001517681 us-gaap:WarrantMember 2019-07-01 2020-06-30 0001517681 PPCB:UnvestedRestrictedStockMember 2020-07-01 2021-06-30 0001517681 PPCB:UnvestedRestrictedStockMember 2019-07-01 2020-06-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2020-07-01 2021-06-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2019-07-01 2020-06-30 0001517681 PPCB:DirectorsAndOfficerMember 2021-06-30 0001517681 PPCB:DirectorsAndOfficerMember 2020-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2017-12-29 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSixteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2017-12-27 2017-12-29 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSixteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2019-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2018-07-01 2019-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2019-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2020-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember PPCB:DecemberTwoThousandAndSeventeenEagleNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSeventeenSecuritiesPurchaseAgreementMember 2020-06-30 0001517681 PPCB:DecemberTwentyNineTwoThousandAndSixteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember 2020-06-30 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2018-07-13 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2018-07-18 2018-07-19 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2018-07-12 2018-07-13 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2019-06-30 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2020-06-30 0001517681 PPCB:JulyThirteenTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:JulyTwoThousandEighteenEagleNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:JuneTwentyNineTwoThousandEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember 2020-06-30 0001517681 PPCB:AugustTwentyNineTwoThousandandEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:AugustTwoThousandEighteenEagleNoteMember 2018-08-29 0001517681 PPCB:AugustTwentyNineTwoThousandandEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:AugustTwoThousandEighteenEagleNoteMember 2018-08-26 2018-08-29 0001517681 PPCB:AugustTwentyNineTwoThousandandEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:AugustTwoThousandEighteenEagleNoteMember 2020-04-01 2020-04-30 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:OctoberTwoTwoThousandAndEighteenEagleNoteMember 2018-10-02 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:OctoberTwoTwoThousandAndEighteenEagleNoteMember 2018-09-29 2018-10-02 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember 2020-04-01 2020-04-30 0001517681 PPCB:NovembeThirtyTwoThousandAndEighteenMecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:NovemberTwoThousandAndEighteenEagleNoteMember 2018-11-30 0001517681 PPCB:NovembeThirtyTwoThousandAndEighteenMecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:NovemberTwoThousandAndEighteenEagleNoteMember 2018-11-26 2018-11-30 0001517681 PPCB:NovembeThirtyTwoThousandAndEighteenMecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:NovemberTwoThousandAndEighteenEagleNoteMember 2020-04-01 2020-04-30 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember 2018-12-23 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember 2020-04-01 2020-04-30 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember srt:MinimumMember 2018-12-23 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember srt:MaximumMember 2018-12-23 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:DepositoryTrustCompanyMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember srt:MinimumMember 2018-12-23 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:DepositoryTrustCompanyMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember srt:MaximumMember 2018-12-23 2018-12-24 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember 2021-06-30 0001517681 PPCB:DecemberTwentyFourTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:EagleEquitiesLLCMember PPCB:DecembeTwoThousandAndEighteenEagleNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementOneMember PPCB:EagleEquitiesLLCMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementOneMember PPCB:EagleEquitiesLLCMember 2021-06-30 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:OctoberTwoThousandEighteenGSNoteMember 2018-10-02 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:OctoberTwoThousandEighteenGSNoteMember 2018-10-03 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:OctoberTwoThousandEighteenGSNoteMember 2018-09-29 2018-10-02 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:OctoberTwoThousandEighteenGSNoteMember PPCB:FirstNoteMember 2018-09-29 2018-10-02 0001517681 PPCB:OctoberTwoTwoThousandAndEighteenSecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:OctoberTwoThousandEighteenGSNoteMember PPCB:SecondNoteMember 2018-09-29 2018-10-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2020-01-22 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2020-01-21 2020-01-22 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember srt:MinimumMember 2020-01-21 2020-01-22 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember srt:MaximumMember 2020-01-21 2020-01-22 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember PPCB:JanuaryTwentyTwoTwentyTwentyGSNoteMember 2020-07-01 2021-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-08-07 2017-08-10 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2017-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2018-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:ConsultantMember 2018-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:ConsultantMember 2019-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2019-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember 2020-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2021-03-15 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:SettlementAndMutualReleaseAgreementMember 2021-06-30 0001517681 PPCB:NovemberTwentySixTwoThousandNineteenSecuritiesPurchaseAgreementMember PPCB:NovemberTwentySixTwoThousandNineteenPowerUpNoteMember 2019-11-26 0001517681 PPCB:NovemberTwentySixTwoThousandNineteenSecuritiesPurchaseAgreementMember PPCB:NovemberTwentySixTwoThousandNineteenPowerUpNoteMember 2019-11-21 2019-11-22 0001517681 PPCB:NovemberTwentySixTwoThousandNineteenSecuritiesPurchaseAgreementMember PPCB:NovemberTwentySixTwoThousandNineteenPowerUpNoteMember 2019-11-25 2019-11-26 0001517681 PPCB:JanuarySevenTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:JanuarySevenTwoThousandTwentyPowerUpNoteMember 2020-01-07 0001517681 PPCB:JanuarySevenTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:JanuarySevenTwoThousandTwentyPowerUpNoteMember 2020-01-12 2020-01-13 0001517681 PPCB:JanuarySevenTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:JanuarySevenTwoThousandTwentyPowerUpNoteMember 2020-01-06 2020-01-07 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-03-12 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-03-04 2020-03-05 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-03-11 2020-03-12 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-01-07 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-06-30 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2021-06-30 0001517681 PPCB:MarchTwelveTwoThousandTwentyPowerUpLendingGroupSecuritiesPurchaseAgreementMember PPCB:MarchTwelveTwoThousandTwentyPowerUpNoteMember 2020-07-01 2021-06-30 0001517681 PPCB:RedstartHoldingsCorpFinancingAgreementMember PPCB:RedstartHoldingsCorpMember 2019-05-23 0001517681 PPCB:RedstartHoldingsCorpFinancingAgreementMember PPCB:RedstartHoldingsCorpMember 2019-05-22 2019-05-23 0001517681 PPCB:RedstartHoldingsCorpFinancingAgreementMember PPCB:RedstartHoldingsCorpMember 2019-06-30 0001517681 PPCB:RedstartHoldingsCorpFinancingAgreementMember PPCB:RedstartHoldingsCorpMember 2020-06-30 0001517681 PPCB:RedstartHoldingsCorpFinancingAgreementMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2019-07-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2019-08-01 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2019-07-31 2019-08-01 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2019-07-29 2019-07-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OdysseyCapitalFundingLLCMember PPCB:JulyTwoThousandNineteenOdysseyNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-08-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-09-04 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-09-03 2019-09-04 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-08-29 2019-08-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember PPCB:FirstWarrantMember 2019-08-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember PPCB:SecondWarrantMember 2019-08-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember PPCB:ThirdWarrantMember 2019-08-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2021-06-30 0001517681 PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2020-07-01 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:OctoberOneTwoThousandNineteenAuctusNoteMember 2019-10-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:OctoberOneTwoThousandNineteenAuctusNoteMember 2019-09-29 2019-10-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2020-12-10 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2020-12-09 2020-12-10 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember srt:MinimumMember 2020-12-09 2020-12-10 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember srt:MaximumMember 2020-12-09 2020-12-10 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:OctoberOneTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:OctoberOneTwoThousandNineteenAuctusNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GWHoldingsGroupLLCMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTenTwoThousandTwentyGWNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember srt:MinimumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember srt:MaximumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-09-15 2020-09-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember 2020-01-13 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember 2020-01-12 2020-01-13 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember srt:MinimumMember 2020-01-12 2020-01-13 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember srt:MaximumMember 2020-01-12 2020-01-13 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryThirteenTwentyTwentyAderAlefNoteMember 2020-07-01 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2020-02-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2020-02-18 2020-02-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2020-03-24 2020-03-25 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember srt:MinimumMember 2020-02-18 2020-02-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember srt:MaximumMember 2020-02-18 2020-02-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:LGCapitalFundingLLCMember 2020-02-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:FebruaryNineteenTwoThousandTwentyLGCapitalNoteMember PPCB:LGCapitalFundingLLCMember 2020-07-01 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:LGCapitalFundingLLCMember 2020-09-08 2020-09-09 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:LGCapitalFundingLLCMember 2020-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:LGCapitalFundingLLCMember 2020-11-29 2020-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2020-12-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryFiveTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-01-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:JanuaryFiveTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-01-04 2021-01-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchSixteenTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-03-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchSixteenTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-03-13 2021-03-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchSixteenTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-01-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:MarchSixteenTwoThousandTwentyOneGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-01-03 2021-01-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember srt:MinimumMember 2020-12-01 2020-12-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember srt:MaximumMember 2020-12-01 2020-12-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2020-12-01 2020-12-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember PPCB:GenevaRothRemarkHoldingsIncMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:DecemberTwoTwoThousandTwentyGenevaRothMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2021-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2020-06-30 0001517681 country:US 2020-07-01 2021-06-30 0001517681 country:US 2019-07-01 2020-06-30 0001517681 PPCB:CaresActMember 2020-03-24 2020-03-27 0001517681 country:US 2021-06-30 0001517681 country:AU PPCB:ExpireInTwoThousandTwentyFourMember 2021-06-30 0001517681 country:AU PPCB:NotExpireMember 2021-06-30 0001517681 country:AU 2019-07-01 2020-06-30 0001517681 country:AU 2020-07-01 2021-06-30 0001517681 country:AU 2021-06-30 0001517681 2021-02-03 0001517681 2021-02-04 0001517681 PPCB:SecurityPurchaseAgreementMember 2020-04-02 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember PPCB:SeriesBWarrantsMember 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember PPCB:SeriesCWarrantsMember 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember PPCB:SeriesAWarrantsMember 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember us-gaap:CommonStockMember 2020-04-02 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember us-gaap:RestrictedStockMember 2020-04-02 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember PPCB:PrefundedWarrantsMember 2020-04-03 0001517681 PPCB:SecurityPurchaseAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember 2020-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember srt:MinimumMember 2020-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember srt:MaximumMember 2020-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember 2021-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember srt:MinimumMember 2021-06-30 0001517681 PPCB:SecurityPurchaseAgreementMember srt:MaximumMember 2021-06-30 0001517681 2020-09-30 0001517681 2020-11-30 0001517681 2020-11-29 2020-11-30 0001517681 PPCB:UnderlyingFinancingAgreementsMember 2020-07-01 2021-06-30 0001517681 PPCB:ConsultingAgreementMember 2020-07-18 2020-07-19 0001517681 PPCB:ConsultingAgreementMember 2020-07-19 0001517681 PPCB:ConsultingAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2020-02-02 2020-02-03 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2020-06-25 2020-06-26 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2020-02-03 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2020-06-26 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2019-07-01 2020-06-30 0001517681 PPCB:ConsultantMember 2021-03-21 2021-03-22 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2020-07-01 2021-06-30 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2021-06-30 0001517681 PPCB:ConsultantMember 2020-07-01 2021-06-30 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2021-03-01 2021-03-31 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2021-06-01 2021-06-30 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2021-03-31 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2021-06-30 0001517681 PPCB:ConsultantMember PPCB:EngagementAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:PrefundedWarrantsMember 2021-06-30 0001517681 PPCB:SeriesBWarrantsMember 2021-06-30 0001517681 PPCB:PrefundedWarrantsMember 2020-07-01 2021-06-30 0001517681 PPCB:TwentySeriesAAndOneSeriesCWarrantsMember 2021-06-30 0001517681 2019-05-01 2019-05-31 0001517681 srt:ChiefExecutiveOfficerMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2021-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2020-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001517681 PPCB:TwoThousandNinteenEquityIncentivePlanMember 2021-06-30 0001517681 PPCB:EmploymentAgreementsMember 2020-07-01 2021-06-30 0001517681 PPCB:EmploymentAgreementsMember 2019-07-01 2020-06-30 0001517681 PPCB:FirstWarrantMember 2019-08-31 0001517681 PPCB:SecondWarrantMember 2019-08-31 0001517681 PPCB:ThirdWarrantMember 2019-08-31 0001517681 2019-09-10 0001517681 2019-09-09 2019-09-10 0001517681 us-gaap:WarrantMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2020-04-02 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesCWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:PrefundedWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesAWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember us-gaap:InvestorMember 2020-03-19 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember PPCB:HolderMember 2020-03-19 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesCWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:FoleyShechterMember 2019-09-25 2019-09-26 0001517681 PPCB:SettlementAgreementMember PPCB:FoleyShechterMember 2021-03-20 2021-03-22 0001517681 PPCB:SettlementAgreementMember PPCB:FoleyShechterMember 2021-03-22 0001517681 PPCB:SettlementAgreementMember PPCB:FoleyShechterMember 2020-07-01 2021-06-30 0001517681 PPCB:RegalConsultingLLCMember 2020-07-01 2021-06-30 0001517681 PPCB:RegalConsultingLLCMember PPCB:TwoThousandAndSeventeenNoteMember 2017-05-31 0001517681 PPCB:RegalConsultingLLCMember PPCB:TwoThousandAndSeventeenNoteMember 2017-05-01 2017-05-31 0001517681 PPCB:SettlementAndMutualReleaseAgreementMember PPCB:RegalConsultingLLCMember 2017-08-10 0001517681 PPCB:SettlementAgreementMember 2021-03-15 0001517681 PPCB:SettlementAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:From2012ThroughThe2014Member 2020-07-01 2021-06-30 0001517681 us-gaap:RoyaltyAgreementTermsMember 2012-06-01 2012-06-30 0001517681 us-gaap:LicenseAgreementTermsMember 2012-06-01 2012-06-30 0001517681 PPCB:NewFiveYearOperatingLeaseAgreementMember 2016-05-05 0001517681 PPCB:NewFiveYearOperatingLeaseAgreementMember PPCB:AUDCurrencyMember 2016-05-03 2016-05-05 0001517681 PPCB:NewFiveYearOperatingLeaseAgreementMember 2016-05-03 2016-05-05 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2019-07-02 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2019-07-01 2019-07-02 0001517681 us-gaap:AccountingStandardsUpdate201602Member PPCB:AUDCurrencyMember 2019-07-01 2019-07-02 0001517681 PPCB:OneYearCollaborationAgreementMember PPCB:EurosMember 2018-09-10 2018-09-13 0001517681 PPCB:OneYearCollaborationAgreementMember 2018-09-10 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:EurosMember 2018-09-10 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2018-09-10 2018-09-13 0001517681 PPCB:EurosMember 2018-07-01 2019-06-30 0001517681 2018-07-01 2019-06-30 0001517681 PPCB:EurosMember 2020-07-01 2021-06-30 0001517681 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember PPCB:NoCustomerMember 2018-09-10 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:EurosMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:EurosMember PPCB:InstallmentOneMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentTwoMember PPCB:EurosMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentTwoMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentThreeMember PPCB:EurosMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentThreeMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentFourMember PPCB:EurosMember 2020-09-29 2020-10-02 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentFourMember 2020-09-29 2020-10-02 0001517681 PPCB:UniversityOfJaenMember PPCB:EurosMember 2020-09-29 2020-10-02 0001517681 PPCB:UniversityOfJaenMember 2020-09-29 2020-10-02 0001517681 us-gaap:SalesRevenueNetMember PPCB:UniversityOfJaenMember us-gaap:RevenueFromRightsConcentrationRiskMember PPCB:NoCustomerMember 2020-09-29 2020-10-02 0001517681 PPCB:CurrentAndFormerDirectorMember 2021-06-30 0001517681 PPCB:CurrentAndFormerDirectorMember 2020-06-30 0001517681 PPCB:FormerDirectorMember 2021-06-30 0001517681 PPCB:FormerDirectorMember 2020-06-30 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:AUDCurrencyMember 2016-05-03 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-03 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:AUDCurrenryMember PPCB:NathanielszMember 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:NathanielszMember 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:AUDCurrenryMember 2020-07-01 2021-06-30 0001517681 PPCB:NorthHorizonPtyLtdMember 2020-07-01 2021-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2015-02-24 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember PPCB:AUDCurrenryMember 2015-02-24 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember PPCB:AUDCurrenryMember 2020-07-01 2021-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember PPCB:AUDCurrenryMember srt:MinimumMember 2018-03-15 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2018-03-15 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember PPCB:AUDCurrenryMember srt:MaximumMember 2018-03-15 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2018-03-15 2018-03-16 0001517681 PPCB:MrsNathanielszMember PPCB:AUDCurrencyMember 2018-01-28 2018-02-01 0001517681 PPCB:MrsNathanielszMember 2018-01-28 2018-02-01 0001517681 PPCB:JamesNathanielszMember PPCB:AUDCurrenryMember 2016-02-24 2016-02-25 0001517681 PPCB:JamesNathanielszMember 2016-02-24 2016-02-25 0001517681 PPCB:MrsNathanielszMember PPCB:AUDCurrenryMember 2019-07-01 2020-06-30 0001517681 PPCB:MrsNathanielszMember 2019-07-01 2020-06-30 0001517681 PPCB:MrsNathanielszMember PPCB:AUDCurrenryMember 2020-07-01 2021-06-30 0001517681 PPCB:MrsNathanielszMember 2020-07-01 2021-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember PPCB:AUDCurrenryMember 2019-05-13 2019-05-14 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2019-05-13 2019-05-14 0001517681 srt:ChiefExecutiveOfficerMember PPCB:AUDCurrenryMember 2018-07-01 2019-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2018-07-01 2019-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember PPCB:AUDCurrenryMember 2020-07-12 2020-07-13 0001517681 srt:ChiefExecutiveOfficerMember PPCB:AUDCurrenryMember 2019-07-01 2020-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2019-07-01 2020-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember us-gaap:SubsequentEventMember 2021-08-11 2021-08-12 0001517681 srt:ChiefExecutiveOfficerMember PPCB:AUDCurrenryMember 2020-07-01 2021-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2020-07-01 2021-06-30 0001517681 srt:ChiefExecutiveOfficerMember PPCB:MrsNathanielszMember 2020-07-01 2021-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2021-08-11 2021-08-12 0001517681 PPCB:EmploymentAgreementMember PPCB:MrNathanielszMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:MrNathanielszMember PPCB:AUDCurrenryMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:RestrictedStocksUnitsRSUMember 2019-05-13 2019-05-14 0001517681 PPCB:EmploymentAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:EmploymentAgreementMember PPCB:AdditionaNathanielszRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMemberMember PPCB:AUDCurrenryMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:InitialKenyonRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:AdditionalKenyonRSUsMember 2019-05-13 2019-05-14 0001517681 PPCB:AUDCurrenryMember 2021-06-30 0001517681 PPCB:ServicesAgreementMember 2020-07-01 2021-06-30 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2021-08-12 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2021-08-11 2021-08-12 0001517681 PPCB:LenderOneMember 2019-07-01 2020-06-30 0001517681 PPCB:LenderTwoMember 2019-07-01 2020-06-30 0001517681 PPCB:LenderThreeMember 2019-07-01 2020-06-30 0001517681 PPCB:LenderOneMember 2020-06-30 0001517681 PPCB:LenderTwoMember 2020-06-30 0001517681 PPCB:LenderThreeMember 2020-06-30 0001517681 PPCB:LenderOneMember 2020-07-01 2021-06-30 0001517681 PPCB:LenderTwoMember 2020-07-01 2021-06-30 0001517681 PPCB:LenderOneMember 2021-06-30 0001517681 PPCB:LenderTwoMember 2021-06-30 0001517681 us-gaap:ConvertibleDebtMember 2021-06-30 0001517681 us-gaap:ConvertibleDebtMember 2020-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2021-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2020-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember 2019-07-01 2020-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2020-07-01 2021-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2019-07-01 2020-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2019-07-01 2020-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2021-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2020-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2020-06-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember 2020-06-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ConvertibleDebtMember 2021-06-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ConvertibleDebtMember 2020-06-30 0001517681 us-gaap:FairValueInputsLevel1Member 2021-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2021-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2021-06-30 0001517681 us-gaap:FairValueInputsLevel1Member 2020-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2020-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001517681 us-gaap:SubsequentEventMember 2021-07-09 2021-09-07 0001517681 us-gaap:SubsequentEventMember PPCB:SeriesBWarrantsMember 2021-07-09 2021-09-07 0001517681 us-gaap:SubsequentEventMember PPCB:SeriesBWarrantsMember 2021-09-07 0001517681 us-gaap:SubsequentEventMember PPCB:TwelveSeriesAAndAWarrantsMember 2021-09-07 0001517681 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-07-01 2021-09-20 0001517681 us-gaap:SubsequentEventMember 2021-09-20 0001517681 us-gaap:SubsequentEventMember srt:MinimumMember 2021-09-20 0001517681 us-gaap:SubsequentEventMember srt:MaximumMember 2021-09-20 0001517681 us-gaap:SubsequentEventMember 2021-09-23 0001517681 us-gaap:SubsequentEventMember PPCB:NathanielszCancellationAgreementMember 2021-08-11 2021-08-12 0001517681 us-gaap:SubsequentEventMember PPCB:MrNathanielszMember PPCB:NathanielszCancellationAgreementMember 2021-07-19 2021-07-20 0001517681 us-gaap:SubsequentEventMember PPCB:MrNathanielszMember PPCB:NathanielszCancellationAgreementMember 2021-08-16 2021-08-17 0001517681 us-gaap:SubsequentEventMember PPCB:MrNathanielszMember PPCB:NathanielszCancellationAgreementMember 2021-08-17 0001517681 PPCB:KenyonCancellationAgreementMember PPCB:DrKenyonMember us-gaap:SubsequentEventMember 2021-08-12 0001517681 PPCB:KenyonCancellationAgreementMember PPCB:DrKenyonMember us-gaap:SubsequentEventMember 2021-08-11 2021-08-12 0001517681 PPCB:ZelingerAmendedAndRestatedDirectorAgreementMember PPCB:JosefZelingerMember us-gaap:SubsequentEventMember 2021-08-11 2021-08-12 0001517681 PPCB:ZelingerAmendedAndRestatedDirectorAgreementMember PPCB:JosefZelingerMember 2021-06-30 0001517681 PPCB:ZelingerAmendedAndRestatedDirectorAgreementMember PPCB:JosefZelingerMember 2020-07-01 2021-06-30 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockOneMember 2021-08-12 0001517681 PPCB:CommonStockOneMember 2021-06-30 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockOneMember 2021-08-11 2021-08-12 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockTwoMember 2021-08-12 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockTwoMember 2021-08-11 2021-08-12 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockThreeMember 2021-09-30 0001517681 us-gaap:SubsequentEventMember PPCB:CommonStockThreeMember 2021-09-01 2021-09-30 0001517681 us-gaap:SubsequentEventMember PPCB:TwoThousandAndTwentyOneSecuritiesPurchaseAgreementMember 2021-08-19 0001517681 us-gaap:SubsequentEventMember PPCB:TwoThousandAndTwentyOneSecuritiesPurchaseAgreementMember 2021-08-18 2021-08-19 0001517681 us-gaap:SubsequentEventMember PPCB:TwoThousandAndTwentyOneSecuritiesPurchaseAgreementMember 2021-09-22 0001517681 us-gaap:SubsequentEventMember PPCB:TwoThousandAndTwentyOneSecuritiesPurchaseAgreementMember 2021-09-21 2021-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PPCB:Integer iso4217:EUR iso4217:AUD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2021

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 000-54878

 

PROPANC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   33-0662986
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)    identification No.)
     
302, 6 Butler Street, Camberwell, VIC Australia   3124
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code   61 03 9882 0780

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered pursuant to section 12(g) of the Act:

Common Stock, par value $0.001 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transaction period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates was $326,763 computed by reference to the closing price of the registrant’s common stock as quoted on the OTCQB maintained by OTC Markets, Inc. on December, 31 2020 (which was $0.26 per share). For purposes of the above statement only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

 

As of September 24, 2021, there were 41,098,787 shares of common stock, par value $0.001 issued and outstanding.

 

Documents Incorporated by Reference: None

 

 

 

 
 

  

PROPANC BIOPHARMA, INC.

 

TABLE OF CONTENTS 

 

  Part I  
     
Item 1. Business 4
Item 1A. Risk Factors 18
Item 1B. Unresolved Staff Comments 18
Item 2. Properties 18
Item 3. Legal Proceedings 18
Item 4. Mine Safety Disclosure 19
     
  Part II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19
Item 6. Selected Financial Data 20
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 25
Item 8. Financial Statements and Supplementary Data 25
Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 26
Item 9A. Controls and Procedures 26
Item 9B. Other Information 28
     
 

Part III

 
     
Item 10. Directors, Executive Officers and Corporate Governance 28
Item 11. Executive Compensation 31
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36
Item 13. Certain Relationships and Related Transactions, and Director Independence 37
Item 14. Principal Accounting Fees and Services 38
     
  Part IV  
     
Item 15. Exhibits, Financial Statement Schedules 39
     
Signatures 43

 

 2 

 

 

Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “intend,” “continue,” “believe,” “expect,” “plan,” “project,” “forecast,” “anticipate,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. The ultimate correctness of these forward-looking statements is dependent upon a number of known and unknown risks and events and is subject to various uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance or achievements expressed or implied by these statements.

 

The following important factors, among others, could affect our future results and events, causing those results and events to differ materially from those views expressed or implied in our forward-looking statements: our ability to continue as a going concern absent new debt or equity financings; our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets; our ability to control costs; our ability to successfully implement our expansion strategies; our current reliance on substantial debt financing that we currently are unable to repay in cash; our ability to obtain adequate new financing; our ability to successfully develop PRP, our lead product candidate; our ability to successfully develop and market our technologies; our ability to obtain and maintain patent protection; our ability to recruit employees and directors with accounting and finance expertise; our dependence on third parties for services; our dependence on key executives; the impact of government regulations, including U.S. Food and Drug Administration regulations; the impact of any future litigation; the availability of capital; changes in economic, business and competitive conditions; and other risks. Any one or more of such risks and uncertainties could have a material adverse effect on us or the value of our common stock.

 

All forward-looking statements included in this Form-10-K are made only as of the date of this Annual Report or as of the date indicated. We do not undertake any obligation to, and may not, publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or which we hereafter become aware of, except as required by law. New risks and uncertainties arise from time to time and we cannot predict these events or how they may affect us. When considering these risks, uncertainties and assumptions, you should keep in mind the cautionary statements contained in this Annual Report and any documents incorporated herein by reference. You should read this Annual Report and the documents that we incorporate by reference into this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

 

 3 

 

 

PART I

 

Item 1. Business

 

GENERAL

 

As used in this Annual Report, references to the “Company,” “Propanc,” “we,” “our,” and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references to our “financial statements” are to our consolidated financial statements included elsewhere in this Annual Report except as the context otherwise requires.

 

We prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, (“U.S. GAAP”). In this Annual Report, references to “$” and “dollars” are to United States dollars.

 

OVERVIEW

 

Propanc Biopharma is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. Our novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

 

Our lead product candidate, PRP, is a variation upon our novel formulation and involves proenzymes, the inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we have conducted successful pre-clinical studies on PRP and also commenced preparation for a clinical study in advanced cancer patients. Subject to us receiving sufficient financing, we plan to begin our Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in the 2021 calendar year. Our plan is to then commence our study preparation process with the contract research organization, analytical lab and trial site(s) selection and to begin our clinical trial application for PRP (“CTA”) compilation in the first calendar quarter of 2022 and complete the CTA compilation and submit the CTA in the first half of 2022. In the second quarter of 2022, we plan to begin the preparation of logistics and trial site initiation visits. Subject to raising additional sufficient capital, we subsequently plan to commence a First-In-Human (FIH), Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in the second half of 2022 calendar year, which study we hope to complete within twelve months thereafter. We intend to develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.

 

PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP produces multiple effects on cancerous cells intended to inhibit tumor growth and potentially stop a tumor from spreading through the body.

 

We received notification from the U.S. Food and Drug Administration (FDA) that PRP had been conferred Orphan Drug Designation for the treatment of pancreatic cancer. This special status is granted when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations.

 

A Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% “cash back” benefit from overseas R&D expenses. The finding relates to the planned Phase 1 clinical trial – Multiple Ascending Dose Studies of proteolytic proenzymes for the treatment of advanced cancer patients suffering from solid tumors planned to be conducted at the Peter MacCallum Center, Melbourne, Australia. Overseas activities to be undertaken include the development of an analytical assay for the quantification of active pharmaceutical ingredients in the Company’s lead product candidate, PRP, and its manufacture of the finished product for the Phase 1 clinical trial.

 

Our POP1 joint research and drug discovery program is designed to produce a backup clinical compound to the lead product candidate, PRP. With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, Propanc Biopharma is undertaking a challenging research project in collaboration with the Universities of Jaén and Granada. We entered into a second two-year joint research and collaboration agreement with the University of Jaén who are undertaking the research activities for the POP1 program.

 

OUR FOCUS

 

Cancer occurs when cells in the body start to divide quickly and uncontrollably with an ability to migrate from one location and spread to distant sites. A cell becomes cancerous when it becomes undifferentiated. The cell forgets to do its job and invests all its energy to proliferating. Unlike normal cells, cancer cells multiply, but do not differentiate.

 

Common cancer therapies take advantage of the uncontrolled proliferation of the cancer cells and kill these cells by targeting the cell division machinery. These therapies are effective but affect healthy cells as well, particularly those with a high rate of cell turnover, inducing undesirable side effects.

 

Our goal is to stop cancer not by targeting tumor cell death, but inducing cell differentiation. This is known as differentiation therapy. The key focus is to convince the malignant cells to stop proliferating and return to do their work as a specific cell type. Differentiation therapy does not target cell death, so healthy cells within the patient will not be compromised, unlike chemotherapeutic drugs or gamma irradiation.

 

Differentiation therapy induces the cancer cells into the pathway of terminal differentiation and eventual senescence (i.e., a non-proliferative state). Differentiation therapy acts not only against cancer cells, but interestingly can turn cancer stem cells (undifferentiated cells) towards completely differentiated (i.e., normal) cells.

 

 4 

 

 

There are natural elements within our body that could help us fight against cancer. Enzymes are natural proteins that stimulate and accelerate biological reactions in the body. Particularly enzymes secreted by the exocrine pancreas that are essential for the digestion of proteins and fats. More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment.

 

We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. PRP is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio.

 

After extensive laboratory research and a limited amount of human data, we have evidence that PRP:

 

  Reduces cancer cell growth via promotion of cell differentiation;
  Enhances cell adhesion and may suppress metastasis progression;
  Exhibited no observable serious side effects and improves patient survival.

 

PRP

 

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung liver, uterine and skin cancers.

 

Mechanism Of Action

 

Metastasis occurs because a program inside the cell, called the Epithelial-Mesenchymal Transition (EMT) is activated, which causes epithelial cancer cells to become invasive and stem cell-like, features which then allow these cancer cells to spread and metastasize. PRP reverses the conversion from an epithelial to a mesenchymal phenotype and, as such, may reduce the metastatic potential of the tumor cells. PRP also promotes the acquisition of a less malignant phenotype, in addition to a decrease in proliferation due to lineage (i.e., direct descent) specific cellular differentiation.

 

Selectivity

 

PRP treatment affects the TGFβ pathway, a significant tumor promoter in late-stage cancer. The likely molecular targets are proteinase-activated-receptors (PARs) type 1 and 2, which are over frequently overexpressed in many types of cancers. Trypsinogen and chymotrypsinogen are activated by proteases in the extracellular matrix of tumor cells. In turn, trypsin (activated trypsinogen) has a preference to activate PAR-2, whilst Chymotrypsin (activated chymotrypsinogen) mainly activates PAR-1.

 

Effects Against Cancer Stem Cells

 

Cancer Stem Cells are resistant to standard treatments because they remain dormant for long periods, then migrate to other organs, and trigger explosive tumor growth, causing the patient to relapse. Approximately eighty percent of cancers are from solid tumors and metastasis is the main cause of patient death. Our unique patented approach is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy.

 

PRP is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy. Traditional cancer therapies act on tumor replicating cells, but not cancer stem cells, so they can rebuild the tumor mass and can migrate to start a new tumor in another organ. PRP stops cancer stem cells so that a tumor loses the ability to generate new cells and therefore the tumor disappears with no option to form a metastatic tumor elsewhere.

 

PRP treatment regulates up to four relevant pathways related to cancer spread and metastasis of cancer stem cells. PRP acts on TGFβ, Hippo, Wnt and Notch pathways. It promotes the up-regulation of RAC1b which avoids the hyper-activation of the p38 pathway induced by the TGFβ pathway, leading to the phosphorylation of YAP, which sequesters B-catenin in the cytoplasm, blocking the canonical Wnt pathway and inhibiting the Notch pathway. That cascade of reactions implies the disruption of the cancer stem cell phenotype and the reversal of the malignant epithelial to mesenchymal transition process that leads to tumor invasion.

 

PRP Impairs Niche Formation and Tumor Initiation

 

The proenzyme treatment inhibits the expression of genes related to the cancer stem cell phenotype, changing these malignant cells toward a more differentiated and less dangerous cellular condition. PRP interferes with the signals that the primary tumor sends to other tissues to prepare the pre-metastatic niche.

 

In Vivo Efficacy of PRP In Pancreatic and Ovarian Tumors

 

The effect of the pro-enzyme formulation PRP at different doses on tumor weight in orthotopically implanted pancreatic and ovary tumors was evaluated. In the pancreatic tumor model, there was significant (*P < 0.05) reduction in mean tumor weight in animals treated for 26 days with trypsinogen/chymotrypsinogen at 83.3/500 mg/kg (30.2 mg; 85.9% inhibition) compared with control (PBS; 214.8 mg). Furthermore, ovary tumor-bearing mice showed a significant (*P < 0.05) reduction in mean tumor weight in animals treated for 21 days with two different doses of trypsinogen/chymotrypsinogen, 9.1/54 mg/kg and 27.5/165 mg/kg, compared with control (PBS). The mean weight of control group tumors was 2062.2 mg while the treated groups presented a mean tumor weight of 1074.2 mg and 957.3 respectively, ranging in a 50% tumor inhibition (52–46%).

 

 5 

 

 

Overview Of Clinical Studies

 

The clinical efficacy of a suppository formulation containing bovine pancreatic pro-enzymes trypsinogen and chymotrypsinogen was evaluated in the context of a UK Pharmaceuticals Special Scheme and the results were published in a peer reviewed journal, Scientific Reports. Clinical effects were studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel cancer and melanoma) after treatment with a rectal formulation of both pancreatic pro-enzymes.

 

No severe or serious adverse events related to the rectal administration were observed. Patients did not experience any hematological side effects as typically seen with classical chemotherapy regimens. No allergic reactions after rectal administration of suppositories were observed.

 

In order to assess the therapeutic activity of rectal administration, overall survival of patients under treatment was compared to the life expectancy assigned to a patient prior to treatment start. Nineteen from 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than their expected, in fact, for the whole set of cancer types, mean survival (9.0 months) was significantly higher than mean life expectation (5.6 months). Although the number of patients per cancer indication is naturally quite low, 3 out of 8 patients with prostate cancer and 5 out of 11 patients with gastrointestinal cancers appear to particularly benefit from the treatment with the proenzyme suppositories.

 

PRP proves to be an in vivo effective and non-toxic anti-tumor treatment, able to inhibit angiogenesis and tumor growth, cancer cell migration and invasiveness. Furthermore, a suppository formulation containing both pancreatic proenzymes increased the life expectancy of advanced cancer patients. Consequently, PRP could have relevant oncological clinical applications for the treatment of solid tumors like advanced pancreatic adenocarcinoma and advanced epithelial ovarian cancer.

 

Cancer Type  

Life Expectation

(months)

 

Survival **

(months)

Pancreatic carcinoma (n = 4)   2   8
  4   *
  <3   7
  <3   4
Ovarian Cancer (n = 7)   4   11
  6   12
  6   11
  <12   38
  <1   1
  4   *
  3   *
Breast Cancer (n = 6)   6   9
  6   *
  2   *
  12   *
  <12   *
  12   *
Colon Rectal Cancer (n = 5)   6   *
  6   *
  12   *
  6   40
  12   *
Gastric Cancer (n = 2)   2   8
  <3   7
Prostate Cancer (n = 8)   4   *
  1   5
  4   *
  <12   *
  12   14
  12   *
  12   *
  12   *
Non-Hodgkin Lymphoma (n = 1)   2   9
Mesothelioma (n = 1)   3   9
Melanoma (n = 2)   6   *
  <3   4
Neuro-endocrine Tumor (n = 1)   10   24
Bladder (n = 2)   <3   *
  12   *
NSCLS (n = 2)   3   5
  6   *
Bowel (n = 2)   <12   *
  <3   3
Small Cell Carcinoma (n = 1)   <12   *
Renal Cancer (n = 1)   <3   *
Abdomen unknown primary (n = 1)   <12   *

 

Overview of clinical studies. Patients who met prognosis of life expectation (*). For the whole set of cancer types, mean survival (9.0 months) was statistically significantly higher than mean life expectation (5.6 months). One way ANOVA (α = 0.05, P < 0.05).

 

 6 

 

 

POP1 JOINT RESEARCH AND DRUG DISCOVERY PROGRAM

 

To date, both proenzymes were synthesized and purified in the laboratory. Once purified, the proenzymes were lyophilized (freeze dried) and each formed a stable, dry white powder. The sequence of proteins of each proenzyme were then determined by mass spectrometry. Larger quantities of the proenzymes were produced with the objective of establishing their combined anti-cancer effects against pancreatic and colorectal cancers. In addition, research activities were transferred to the MEDINA Foundation Research Center to investigate the potential to scale up production of the recombinant proenzymes from the expression of the novel expression system, which is currently ongoing. MEDINA is a Non-Profit Research Organization established in 2008 through a public-private alliance between the Regional Government of Andalusia, Spain, the pharmaceutical company Merck Sharp & Dohme de España S.A. (MSD), and the University of Granada. Medina’s scientific platforms support the development of multidisciplinary research programs in Microbiology, Natural Product Chemistry and Screening & Target Validation.

 

We are elucidating the molecular pathways involved in the proenzymes anti-tumor efficacy and study how proenzymes interact with the pre-metastatic tumor niche, focusing on the interaction and suppression of tumor associated cells, like cancer-associated fibroblasts and macrophages. A pre-metastatic tumor niche is an environment in a secondary organ conducive to the metastasis of a primary tumor. Such a niche provides favorable conditions for growth, and eventually metastasis, in an otherwise foreign and hostile environment for the primary tumor cells. Metastasis remains the main cause of patient death from solid tumors for cancer sufferers.

 

To achieve this, we are using integrated tumor models in a microfluidics chip by obtaining 3-dimensional bio-impression samples from patients with advanced solid tumors, developed at the Centre for Biomedical Research, University of Granada, Granada, Spain. As well as explaining the mechanism of action by which proenzymes exert their anti-cancer effects, it also confirms whether proenzymes penetrate into the tumor microenvironment and exert their effects. At the same time, it confirms the selectivity of the drug on solid tumors, by targeting cancer cells and leaving healthy cells alone.

 

To date, our investigation has confirmed that proenzyme therapy is effective against cancer stem cells, which are the cells responsible for the formation of secondary tumors through metastasis. They were also observed to be effective against cancer cells within the primary tumor, whilst also leaving non-tumor cells alone. The final part of the investigation is to determine the effects of the proenzymes against both these cancerous cell types within the tumor microenvironment.

 

Our Joint Research Team successfully published data confirming the anti-tumor potential of a mixture of trypsinogen and chymotrypsinogen. Treatment with proenzymes sensitizes cancer stem cells, which may allow standard treatment approaches like chemotherapy and radiotherapy to be more effective.

 

Our vision is to produce a backup product candidate to PRP which can further stabilize and enhance the effects of the proenzymes when administered to patients. Our scientific researchers are in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen with this expression system.

 

PRP TARGET INDICATIONS

 

The management of cancer differs widely, with a multitude of factors impacting the choice of treatment strategy. Some of those factors include:

 

  the type of tumor, usually defined by the tissue in the body from which it originated;
  the extent to which it has spread beyond its original location;
  the availability of treatments, driven by multiple factors including cost, drugs approved, local availability of suitable facilities, etc.;
  regional and geographic differences;
  whether the primary tumor is amenable to surgery, either as a potentially curative procedure, or as a palliative one; and
  the balance between potential risks and potential benefits from the various treatments and, probably most importantly, the patient’s wishes.

 

For many patients with solid cancers, such as breast, ovarian, colorectal, lung and pancreatic cancer, surgery is frequently the first treatment option, often followed by first line chemotherapy with or without radiotherapy. While hopefully such procedures are curative, in many instances the tumor returns, and second line treatment strategies are chosen in an effort to achieve a degree of control over the tumor. In most instances, the benefit is temporary, and eventually the point is reached where the patient’s tumor either fails to adequately respond to treatment, or the treatment has unacceptable toxicity which severely limits its usefulness.

 

 7 

 

 

Should the planned Phase I, II and III clinical trials confirm the efficacy of PRP, along with the favorable safety and tolerability profile suggested by pre-clinical studies conducted to date, we believe our product will have utility in a number of clinical situations including:

 

  1. In the early-stage management of solid tumors, most likely as part of a multi-pronged treatment strategy in combination with existing therapeutic interventions;
  2. As a product that can be administered long term for patients following standard treatment approaches, such as surgery, or chemotherapy, in order to prevent or delay recurrence; and
  3. As a preventative measure for patients at risk of developing cancer based on genetic screening.

 

In the near term as part of our planned Phase I, II and III clinical trials, we plan to target patients with solid tumors, most likely ovarian and pancreatic, for whom other treatment options have been exhausted. This is a common approach by which most new drugs for cancer are initially tested. Once efficacy and safety has been demonstrated in this patient population, exploration of the potential utility of the drug in earlier stage disease can be undertaken, together with investigation of the drug’s utility in other types of cancers, such as gastro-esophageal tumors, colon or rectal carcinoma might be conducted. A Phase II study in a back-up indication, such as advanced therapy refractant prostate cancer will also be considered. This indication is based on positive preclinical pharmacology studies.

 

Pancreatic Cancer

 

Pancreatic cancer is one of the most lethal malignancies with a median survival of less than 6 months and a 5-year survival rate of less than 5%. The lethal nature of this disease stems from its propensity to rapidly disseminate to the lymphatic system and distant organs. This aggressive biology and resistance to conventional and targeted therapeutic agents leads to a typical clinical presentation of incurable disease at the time of diagnosis.

 

Pancreatic cancer has claimed notoriety over the last decades by proving to be one of the most recalcitrant solid tumors. As an indicator of its lethality, pancreatic cancer accounts for less than 3% of new cancers diagnosed annually in developed countries, yet it is the third leading cause of cancer related mortality.

 

Since pancreatic cancer is an essentially fatal condition, disease duration is roughly equivalent with survival time. The median time of survival of patients with pancreatic cancer depends on the extend of disease at the time of diagnosis and ranges from 11-20 months for patients who qualified for surgical resection (Stage I/II), to 6-11 months for patients with locally advanced disease (Stage III), and only 2-6 months for patients with metastatic disease (Stage IV) (Amikura 1995, Richter 2003). Taking these low survival times into consideration, the yearly incidence rates for pancreatic cancer are considered the more relevant measure for this disease.

 

Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data are collected by the National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), and the North American Association of Central Cancer Registries (NAACCR). In 2015, a total of more than 1,500,000 new cancer cases and more than 500,000 cancer deaths will occur in the United States. Amongst these, a total of almost 50.000 new cases of pancreatic cancer (3.33% of new cancer cases) have been estimated, which will result in more than 40,000 deaths (8% of cancer deaths). This means only 20% survival rate of patients diagnosed with pancreatic cancer.

 

Ovarian Cancer

 

Ovarian cancer is a generic term that can be used for any cancer involving the ovaries, arising from one of the several different cell types of ovaries, including germ cells, specialized gonadal stromal cells and epithelial cells. Epithelial ovarian cancer accounts for 90 percent of ovarian cancers and is responsible for most ovarian cancer related deaths. Furthermore, several subtypes of ovarian cancer have been described according to different risk factors, different genetic mutations, different biological behaviors and different prognoses. This heterogeneity of the disease has impeded progress in the prevention, early detection, treatment and management of ovarian cancer.

 

Ovarian cancer is the seventh most commonly diagnosed cancer among women in the world and accounts for an estimated 239,000 new cases and 152,000 deaths worldwide annually, of which 21,290 new cases and 14,180 related deaths are estimated to occur in the USA alone. The disease typically presents at late stage when the 5-year relative survival rate is only 29%. Few cases (15%) are diagnosed with localized tumor (stage 1), when the 5-year survival rate is 92%. Strikingly, the overall 5-year relative survival rate generally ranges between 30%–40% across the globe and has seen only very modest increases since 1995.

 

PRP DEVELOPMENT STRATEGY

 

Our goal is to undertake early-stage clinical development of PRP through to a significant value inflection point, where the commercial attractiveness of a drug in development, together with a greater likelihood of achieving market authorization, may attract potential interest from licensees seeking to acquire new products. Such value inflection points in the context of cancer drugs are typically at the point where formal, controlled clinical trials have demonstrated either ‘efficacy’ or ‘proof of concept’ – typically meaning that there is controlled clinical trial evidence that the drug is effective in the proposed target patient population, has an acceptable safety profile, and is suitable for further development. From a ‘big picture’ perspective, it is our intention to progress the development of our technology through the completion of our planned Phase IIa clinical trials and then to seek a licensee for further development beyond that point.

 

 8 

 

 

As part of that commercial strategy, we will:

 

  continue research and development to build our existing intellectual property portfolio, and to seek new, patentable discoveries;
  seek to ensure all product development is undertaken in a manner that makes its products approvable in the major pharmaceutical markets, including the U.S., Europe, the UK, Australia and Japan;
  aggressively pursue the protection of our technology through all means possible, including patents in all major jurisdictions, and potentially trade secrets; and
  make strategic acquisitions to acquire new companies that have intellectual property or products that complement our future goals.

 

PRP DEVELOPMENT PLAN AND MILESTONES

 

We plan to progress PRP down a conventional early-stage clinical development pathway for:

 

  regulatory and/or ethics approval to conduct a Phase Ib study; and
  Phase IIa multiple escalating dose studies to investigate the safety, tolerability, and pharmacokinetics of PRP administered intravenously to patients.

 

Preclinical development has been completed, including pharmacology and safety toxicology studies, process development activities and bioanalytical method development. The full-scale GMP (Good Manufacturing Practice) finished product manufacture of PRP will be completed in preparation for the FIH Phase Ib study. Validation of the bioanalytical method will also be completed prior to lodging our first clinical trial application (CTA) which we plan to undertake at the Peter Mac Cancer Center in Melbourne, Victoria, Australia’s biggest cancer hospital. Propanc Biopharma is collaborating with contract research organizations, manufacturing partners and consultants to complete activities prior to preparing the CTA for the Phase Ib study.

 

The Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by medical oncologists specializing in pancreatic and ovarian cancers, from the University Hospital of Jaén, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), multi-trial center studies for each target indication. The expressions of interest were confirmed after their evaluation of Propanc’s scientific literature supporting the use of proenzymes in pancreatic and ovarian cancers. The Phase IIa POC studies will be conducted after the Phase Ib dose escalation study investigating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed at the Peter Mac Cancer Center.

 

In Australia, we receive up to 43.5% “cash-back” benefit in the form of a refund of their qualified research and development costs and expenses. The Company received a refund of $151,767 AUD ($113,415 USD) and $199,834 AUD ($134,728 USD) for the years ended June 30, 2021 and 2020 respectively. We are continuing to evaluate all options to conduct our planned clinical trials in the most cost-efficient manner, while striving to minimize dilution to our stockholders.

 

We anticipate reaching the Phase IIa proof of concept milestone in approximately three to four years, subject to regulatory approval in Europe, and the results from our research and development and licensing activities.

 

Our overhead and expenses are likely to increase from its current level as PRP progresses down the development pathway. This increase will be driven by the need to increase our internal resources in order to effectively manage our research and development activities.

 

Anticipated timelines

 

In second quarter of 2022 calendar year, we anticipate the submission of the Clinical Trial Application for PRP. We anticipate receiving approval of such application in the first half of 2022. Following the clinical trial application, we plan to commence our Study Preparation, including CRO Selection and Contracts, Analytical Lab Selection Contracts and Trial Sites Selection and Contracts. In connection with the Clinical Trial Application, this product will be part of our Investigation Medicinal Product Dossier, Study Protocol and Investigator’s Brochure. In the second half of 2022 calendar year, we hope to complete the Study Preparation together with the Preparation of Logistics and Trial Sites Initiation Visits and complete our clinical trial application review. Commencing in the second half of 2022 calendar year, we intend to initiate a Phase Ib study in advanced cancer patients with solid tumors and the anticipated costs will be approximately $6.5 million. We will need to raise additional financing to fund our planned Phase I, II and III clinical trials and for working capital.

 

 9 

 

 

Research Activity   Timeline
Clinical Trial Application (CTA)   Nov ‘21 - Apr ‘22
Investigational Medicinal Product Dossier  
Phase Ib Clinical Study Protocol  
Investigator’s Brochure  
CTA Compilation   Mar - May ‘22
CTA submission   May ‘22
CTA Approval   Jun ‘22
CTA Review   June ‘22 – Jul ‘22
Contract Research Organization & Contracts   Jan – May ‘22
Analytical Laboratory Selection & Contracts  
Trial Site Selection & Contracts  
Preparation of Logistics   May – Sep ‘22
Trial Site Initiation Visits  
First Patient/First Visit   Sep ‘22

 

POP1 JOINT RESEARCH AND DRUG DISCOVERY PROGRAM

 

As outlined previously, a joint research and drug discovery program has been established with our collaborators at the Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells as a consequence of being exposed to our proenzyme formulation. The objective of this work is to understand at the molecular level the targets of our proenzyme formulation, thereby providing the opportunity for new, patentable drugs which can be developed further. We plan to commence a targeted drug discovery program utilizing the identified molecular target to search for novel anticancer agents.

 

One specific objective of the project is to synthesize both proenzymes by an in vivo system to produce crystalized proteins that could be maintained for long periods without suffering degradation, even in absence of refrigeration. This will be particularly useful for a longer shelf life as well as global distribution of the drug product, particularly in warmer climates and developing regions where refrigeration may not be available.

 

The POP1 joint research and drug discovery program has produced synthetic recombinant versions of the two proenzymes, trypsinogen and chymotrypsinogen. Propanc Biopharma’s joint scientific researchers are developing a novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic versions will be tested against the naturally derived proenzymes from bovine origin.

 

FINANCIAL OBJECTIVES

 

Multiple factors, many of which are outside of our control, can impact our ability to achieve our target objectives within the planned time and budgetary constraints. Subject to these caveats, our objective is to complete our planned Phase IIa study for PRP within the proposed budget.

 

We primarily outsource services, skills and expertise to third parties as required to achieve our scientific and corporate objectives. As the business grows and gains more personnel, outsourcing will continue to be the preferred model, where fixed and variable costs are carefully managed on a project-by-project basis. This means our research and development activities are carried out by third parties. Additional third parties with specific expertise in research, compound screening and manufacturing (including raw material suppliers) have been contracted as required.

 

CORPORATE STRATEGY

 

Our initial focus is to organize, coordinate and finance the various parts of our drug development pipeline. New personnel will be carefully introduced into our Company over a period of time as our research and development activities expand. They will have specific expertise in product development, manufacture and formulation, regulatory affairs, toxicology, clinical operations and business development (including intellectual property management, licensing and other corporate activities). In the first instance, additional clinical management and development expertise is likely to be required for our lead product. Therefore, we anticipate an increase in employees in order to effectively manage our contractors as the projects progress down the development pathway.

 

This outsourcing strategy is common in the biotechnology sector, and is an efficient way to obtain access to the necessary skills required to progress a project, in particular as the required skills change as the project progresses from discovery, through manufacturing and non-clinical development and into clinical trials. We anticipate that we will continue to use this model, thereby retaining the flexibility to contract in the appropriate resource as and when required.

 

We intend to seek and identify potential licensing partners for our product candidates as they progress through the various development stages, reaching certain milestones and value inflection points. If a suitable licensee is identified, a potential licensing deal could consist of payments for certain milestones, plus royalties from future sales if the product is able to receive approval from the relevant regulatory authorities where future product sales are targeted. We intend to seek and identify potential licensees based on the initial efficacy data from Phase II clinical trials. To accomplish this objective, we have commenced discussions with potential partners in our current preclinical phase of development.

 

 10 

 

 

As part of our overall expansion strategy, from time to time, we investigate potential intellectual property acquisition opportunities to expand our product portfolio. While our initial focus is on the development of PRP as the lead product candidate, potential product candidates may also be considered for future preclinical and clinical development. These potential opportunities have arisen from other research and development organizations, which either own existing intellectual property or are currently developing new intellectual property, which may be of interest to us. These opportunities are possible new cancer treatments that are potentially less toxic than existing treatment approaches and are able to fill an existing gap in the treatment process, such as a systemic de-bulking method which could reduce the size and threat of metastases to a more manageable level for late-stage cancer patients.

 

We believe these potential treatment approaches will be complementary to existing treatment regimens and our existing product candidate, PRP. No formal approaches have been made at this stage and it is unknown whether we will engage in this discussion in the near future. However, as PRP progresses further down the development pathway, we intend to assess future opportunities that may arise to use the expertise of our management and scientific personnel for future prospective research and development projects.

 

CURRENT OPERATIONS

 

We are at a pre-revenue stage. We do not know when, if ever, we will be able to commercialize our products and begin generating revenue. We are focusing our efforts on organizing, coordinating and financing the various aspects of the drug research and development program outlined earlier in this document. In order to commercialize our products, we must complete preclinical development, Phase Ib, IIa and IIb clinical trials in Europe, the U.S., United Kingdom, Australia or elsewhere, and satisfy the applicable regulatory authority that PRP is safe and effective. If the results from the Phase II trials are convincing, we will seek conditional approval from the regulatory authorities sooner. Therefore, from the time we commence clinical trials, we estimate that this will take approximately three to four years if we seek conditional approval upon completion of Phase II trials. As described previously, when we advance our development projects sufficiently down the development pathway and achieve a major increase in value, such as obtaining interim efficacy data from Phase II clinical trials, we will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.

 

CURRENT THERAPIES

 

We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors, which is cancer that originates in organs or tissues other than bone marrow or the lymph system. Common cancer types classified as solid tumors include lung, colorectal, ovarian cancer, pancreatic cancer and liver cancers. In each of these indications, there is a large market opportunity to capitalize on the limitations of current therapies.

 

Current therapeutic options for the treatment of cancer offer, at most, a few months of extra life or tumor stabilization. Some experts believe that drugs that kill most tumor cells do not affect cancer stem cells, which can regenerate the tumor (e.g., chemotherapy). Studies are revealing the genetic changes in cells that cause cancer and spur its growth. This research is providing scientific researchers with many potential targets for drugs. Tumor cells, however, can develop resistance to drugs.

 

Limitations of Current Therapies

 

PRP was developed because of the limitation of current cancer therapies. While surgery is often safe and effective for early-stage cancer, many standard therapies for late-stage cancer urgently need improvement; current treatments generally provide modest benefits, and frequently cause significant adverse effects. Our focus is to provide oncologists and their patients with therapies for metastatic cancer which are more effective than current therapies, and which have a substantially reduced side effect profile.

 

While progress has been made within the oncology sector in developing new treatments, the overall cancer death rate has only improved by 7% over the last 30 years.

 

Most of these new treatments have some limitations, such as:

 

  1. significant toxic effects;
  2. expense; and
  3. limited survival benefits.

 

We believe that our treatment will provide a competitive advantage over the following treatments:

 

  Chemotherapeutics: Side effects from chemotherapy can include pain, diarrhea, constipation, mouth sores, hair loss, nausea and vomiting, as well as blood-related side effects, which may include a low cell count of infection fighting white blood cells (neutropenia), low red blood cell count (anemia), and low platelet count (thrombocytopenia). Our goal is to demonstrate that our treatment will be more effective than chemotherapeutic and hormonal therapies with fewer side effects.
  Targeted therapies: The most common type is multi-targeted kinase inhibitors (molecules which inhibit a specific class of enzymes called kinases). Common side effects include fatigue, rash, hand–foot reaction, diarrhea, hypertension and dyspnoea (shortness of breath). Further, tyrosine kinases inhibited by these drugs appear to develop resistance to inhibitors. While the clinical findings with PRP are early and subject to confirmation in future clinical trials, no evidence has yet been observed of the development of resistance by the cancer to PRP.

 

 11 

 

 

  Monoclonal antibodies: Development of monoclonal antibodies is often difficult due to safety concerns. Side effects that are most common include skin and gastro-intestinal toxicities. For example, several serious side effects from Avastin, an anti-angiogenic cancer drug, include gastrointestinal perforation and dehiscence (e.g., rupture of the bowel), severe hypertension (often requiring emergency treatment) and nephrotic syndrome (protein leakage into the urine). Antibody therapy can be applied to various cancer types, but can also be limited to certain genetic sub populations in many instances.
  Immunotherapy: There is a long history of attempts to develop therapeutic cancer vaccines to stimulate the body’s own immune system to attack cancer cells. While these products generally do not have the poor safety profile of standard therapeutic approaches, only a small number of them are FDA-approved and available compared to the number of patients diagnosed with cancer. Furthermore, only a relatively small number of the patient population is eligible to receive and subsequently respond to treatment, as defined by preventing tumor growth.

 

MARKET OPPORTUNITY

 

The global metastatic cancer treatment market is predicted to reach $111 Billion by 2027 by Emergen Research. Demand for new cancer products can largely be attributed to a combination of a rapidly aging population in western countries and changing environmental factors, which together are resulting in rising cancer incidence rates. Worldwide, the World Health Organization estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. As such, global demand for new cancer treatments which are effective, safe and easy to administer is rapidly increasing. Our treatment will potentially target many aggressive tumor types for which little or few treatment options exist.

 

We plan to target patients with solid tumors, most likely pancreatic and ovarian tumors, for whom other treatment options have been exhausted. Globally these cancers resulted in over 673,255 deaths in 2020, according to the World Health Organization. With such a high mortality rate, a substantial unmet medical need exists for new treatments. Once the efficacy and safety of PRP has been demonstrated in late-stage patient populations, we plan to undertake exploration of the utility of the drug in earlier stage disease, together with investigation of the drug’s utility in other types of cancer.

 

Anticipated Market Potential

 

It is difficult to estimate the size of the market opportunity for this specific type of product as a clinically proven, pro-enzyme formulated suppository marketed to oncologists across global territories for specific cancer indications, to the best of management’s knowledge, has not been previously available. However, the markets for potential market for pancreatic and ovarian cancers may be characterized as follows:

 

  The world market for pancreatic cancer drugs is projected to grow to $4.2 billion by the year 2025, according to Grandview Research. Major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The developments performed by the companies are helping the market to grow in the coming years.
  The global market for ovarian cancer drugs expected to reach $10.1 billion by 2027, according to iHealthcareAnalyst. This will be driven by continued uptake and expected launches of the approved PARP (poly adenosine diphosphate-ribose polymerase) inhibitors. Major competitors operating in the global ovarian cancer treatment market include AbbVie, Inc., AstraZeneca plc (Acerta Pharma), Boehringer Ingelheim GmbH, Chugai Pharmaceutical Co., Ltd., Clovis Oncology, Five Prime Therapeutics, Inc., GlaxoSmithKline plc (Tesaro), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Mateon Therapeutics, Inc., Merck & Co., Inc., Novartis AG, Novogen Limited, Oasmia Pharmaceuticals, Inc., Pfizer, Inc., PharmaMar S.A, and Roche Holding AG.

 

New products can be defined as addition-in-class, advance-in-class, or first-in-class, depending on their degree of innovation. Addition-in-class products, defined as new Active Pharmaceutical Ingredients (API) with established mechanisms of action, are often clinically important and highly commercially successful. Advance-in-class product innovation, defined as significantly differentiated and innovative new APIs, albeit with established mechanisms of action, remains a highly attractive strategy. However, first-in-class innovation, defined as products with a molecular target and/or mechanism of action not found in any approved products globally, remains the key product development strategy in terms of providing the greatest degree of differentiation, extending to a first-mover advantage and potentially the capture of significant market share.

 

Based on the current situation for these two markets, we believe there is an attractive opportunity in both the pancreatic and ovarian cancer market sectors for the introduction of a first-in-class, clinically proven product which can achieve new benefits for patients in terms of survival and quality of life. The current concentration of products suggests oncologists may be willing to try newly approved products, particularly if they can exhibit a favorable safety profile, although substantive R&D activities will be necessary to both obtain regulatory approval, and to generate the clinical safety and efficacy data needed to convince clinicians to use a new product.

 

 12 

 

 

LICENSE AGREEMENTS

 

University of Bath

 

We previously sponsored a collaborative research project at University of Bath to investigate the cellular and molecular mechanisms underlying the potential clinical approach of our proprietary proenzyme formulation. As a result of this undertaking, we entered into a Commercialization Agreement with University of Bath (UK), dated November 12, 2009 (the “Commercialization Agreement”), where, initially, we held an exclusive license with Bath University, and where we and University of Bath co-owned the intellectual property relating to our proenzyme formulations. The Commercialization Agreement originally provided for University of Bath to assign the Patents (as defined therein) to Propanc in certain specified circumstances, such as successful completion of a clinical trial and commencement of a Phase II (Proof of Concept) clinical trial.

 

On June 14, 2012, Propanc and University of Bath agreed to an earlier assignment to us of the patents pursuant to an Assignment and Amendment Deed, on the provision that Bath University retains certain rights arising from the Commercialization Agreement, as follows:

 

  University of Bath reserves for itself (and its employees and students and permitted academic sub-licensees with respect to research use) the non-exclusive, irrevocable, worldwide, royalty free right to use the patents for research use;
  The publication rights of University of Bath specified in the contract relating to the original research made between the parties with an effective date of July 18, 2008 shall continue in force;
  Propanc shall pay to University of Bath a royalty of two percent of any and all net revenues;
  Propanc shall use all reasonable endeavors to develop and commercially exploit the patents for the mutual benefit of University of Bath and Propanc to the maximum extent throughout the covered territory and in any additional territory and to obtain, maintain and/or renew any licenses or authorizations that are necessary to enable such development and commercial exploitation. Without prejudice to the generality of the foregoing, Propanc shall comply with all relevant regulatory requirements in respect of its sponsoring and/or performing clinical trials in humans involving the administration of a product or materials within a claim of the patents; and
  Propanc shall take out with a reputable insurance company and maintain liability insurance coverage prior to the first human trials.

 

In consideration of such assignment, we agreed to pay royalties of 2% of net revenues to University of Bath. Additionally, we agreed to pay 5% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement.

 

University of Jaén

 

We have established a collaboration with the University of Jaén to carry out a Research Project aimed at the synthetic development of PRP and its subsequent validation. The University of Jaén is providing scientific research activities the Department of Health Sciences, which provides the necessary technical and human resources in order to carry out the programmed works. A Collaboration Agreement (the “Collaboration Agreement”) according was established, dated October 1, 2020, with the main objective for the synthetic development of PRP and its subsequent validation. To that end, there shall be established a pre-clinical protocol of safety evaluation and antitumor efficacy on cancer stem cells and in orthotopic xenotransplantations derived from cancer stem cells isolated from tumor cell lines, of a newly developed synthetic formulation based on the two pancreatic zymogens.

 

The ownership of potential intellectual property rights that may arise as a result of the knowledge obtained through the project will belong to Propanc. In consideration for payment of the compensation, the University of Jaén hereby assigns and agrees to do all things reasonably required to assign to the contracting entity all industrial property rights arising from the Project.

 

In return for ownership of the entire right and title in all industrial property rights arising from the Project, Propanc agrees to pay the University of Jaén two percent (2%) of the net sales of any products sold by the contracting entity which fall within the scope of the protection of such industrial property rights.

 

Future Agreements

 

We continue to learn the properties of proenzymes with the long-term aim of screening new compounds for development. We anticipate engaging in future discussions with several technology companies who are progressing new developments in the oncology field as potential additions to our product line. Initially targeting the oncology sector, our focus is to identify and develop novel treatments that are highly effective targeted therapies, with few side effects as a result of toxicity to healthy cells.

 

INTELLECTUAL PROPERTY

 

The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea, India and Brazil. In Canada, the patent application remains under examination.

 

 13 

 

 

In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered national phase in October 2018.

 

Presently, there are 31 granted patents and 34 patents under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP.

 

Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer.

 

REGULATORY MATTERS

 

United States

 

Government oversight of the pharmaceutical industry is usually classified into pre-approval and post-approval categories. Most of the therapeutically significant innovative products marketed today are the subject of New Drug Applications (“NDA”). Preapproval activities, based on these detailed applications, are used to assure the product is safe and effective before marketing. In the United States, The Center for Drug Evaluation and Research (“CDER”), is the FDA organization responsible for over-the- counter and prescription drugs, including most biological therapeutics, and generic drugs.

 

Before approval, the FDA may inspect and audit the development facilities, planned production facilities, clinical trials, institutional review boards and laboratory facilities in which the product was tested in animals. After the product is approved and marketed, the FDA uses different mechanisms for assuring that firms adhere to the terms and conditions of approval described in the application and that the product is manufactured in a consistent and controlled manner. This is done by periodic unannounced inspections of production and quality control facilities by FDA’s field investigators and analysts.

 

Federal Food, Drug and Cosmetic Act and Public Health Service Act

 

Prescription drug and biologic products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the testing, manufacturing, safety, efficacy, labelling, storage, record keeping, advertising and promotion of such products under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and their implementing regulations. The process of obtaining FDA approval and achieving and maintaining compliance with applicable laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply with applicable FDA or other requirements may result in refusal to approve pending applications, a clinical hold, warning letters, civil or criminal penalties, recall or seizure of products, partial or total suspension of production or withdrawal of the product from the market. FDA approval is required before any new drug or biologic, including a new use of a previously approved drug, can be marketed in the United States. All applications for FDA approval must contain, among other things, information relating to safety and efficacy, stability, manufacturing, processing, packaging, labelling and quality control.

 

New Drug Applications (“NDAs”)

 

The FDA’s NDA approval process generally involves:

 

  Completion of preclinical laboratory and animal testing in compliance with the FDA’s good laboratory practice, or GLP, regulations;
  Submission to the FDA of an investigational new drug (“IND”) application for human clinical testing, which must become effective before human clinical trials may begin in the United States;
  Performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed product for each intended use;
  Satisfactory completion of an FDA pre-approval inspection of the facility or facilities at which the product is manufactured to assess compliance with the FDA’s “current good manufacturing practice” (“CGMP”) regulations; and
  Submission to and approval by the FDA of an NDA.

 

The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot guarantee that any approvals for our product candidates will be granted on a timely basis, if at all. Preclinical tests include laboratory evaluation of toxicity and immunogenicity in animals. The results of preclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND application to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Our submission of an IND may not result in FDA authorization to commence clinical trials. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board (“IRB”) covering each medical center proposing to conduct clinical trials must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive “good clinical practice” (“GCP”) regulations, which include requirements that all research subjects provide informed consent and that all clinical studies be conducted under the supervision of one or more qualified investigators.

 

 14 

 

 

For purposes of an NDA submission and approval, human clinical trials are typically conducted in the following sequential phases, which may overlap:

 

  Phase I: Initially conducted in a limited population to test the product candidate for safety and dose tolerance;
  Phase II: Generally conducted in a limited patient population to identify possible adverse effects and safety risks, to determine the initial efficacy of the product for specific targeted indications and to determine optimal dosage. A Phase IIa trial is a non-pivotal, exploratory study that assesses biological activity as its primary endpoint. A Phase IIb trial is designed as a definite dose finding study with efficacy as the primary endpoint. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive Phase III clinical trials;
  Phase III: Commonly referred to as pivotal studies. When Phase II evaluations demonstrate that a dose range of the product is effective and has an acceptable safety profile, Phase III clinical trials are undertaken in large patient populations to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically-dispersed clinical trial sites. Generally, replicate evidence of safety and effectiveness needs to be demonstrated in two adequate and well-controlled Phase III clinical trials of a product candidate for a specific indication. These studies are intended to establish the overall risk/benefit ratio of the product and provide adequate basis for product labelling; and
  Phase IV: In some cases, the FDA may condition approval of a NDA on the sponsor’s agreement to conduct additional clinical trials to further assess the product’s safety, purity and potency after NDA approval. Such post-approval trials are typically referred to as Phase IV clinical trials.

 

Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. Concurrent with clinical studies, sponsors usually complete additional animal studies and must also develop additional information about the product and finalize a process for manufacturing the product in commercial quantities in accordance with CGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Moreover, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

 

The results of product development, preclinical studies and clinical trials, along with the aforementioned manufacturing information, are submitted to the FDA as part of a NDA. NDA’s must also contain extensive manufacturing information. Under the Prescription Drug User Fee Act (“PDUFA”), the FDA agrees to specific goals for NDA review time through a two-tiered classification system, Standard Review and Priority Review. Standard Review is applied to products that offer at most, only minor improvement over existing marketed therapies. Standard Review NDAs have a goal of being completed within a ten-month timeframe, although a review can take significantly longer. A Priority Review designation is given to products that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A Priority Review takes the FDA six months to review a NDA. It is likely that our product candidates will be granted Standard Reviews. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.

 

The FDA may deny approval of a NDA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or additional pivotal Phase III clinical trials. Even if such data is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials is not always conclusive and the FDA may interpret data differently than Propanc. Once issued, product approval may be withdrawn by the FDA if ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase IV clinical trials, Risk Evaluation and Mitigation Strategies (“REMS”), and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. Products may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to the drug, including changes in indications, labelling or manufacturing processes or facilities, approval of a new or supplemental NDA may be required, which may involve conducting additional preclinical studies and clinical trials.

 

Other U.S. Regulatory Requirements

 

After approval, products are subject to extensive continuing regulation by the FDA, which include company obligations to manufacture products in accordance with GMP, maintain and provide to the FDA updated safety and efficacy information, report adverse experiences with the product, keep certain records, submit periodic reports, obtain FDA approval of certain manufacturing or labeling changes and comply with FDA promotion and advertising requirements and restrictions. Failure to meet these obligations can result in various adverse consequences, both voluntary and FDA-imposed, including product recalls, withdrawal of approval, restrictions on marketing and the imposition of civil fines and criminal penalties. In addition, later discovery of previously unknown safety or efficacy issues may result in restrictions on the product, manufacturer or NDA holder.

 

 15 

 

 

Propanc, and any manufacturers of our products, are required to comply with applicable FDA manufacturing requirements contained in the FDA’s GMP regulations. GMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. The manufacturing facilities for our products must meet GMP requirements to the satisfaction of the FDA pursuant to a pre-approval inspection before Propanc can use them to manufacture products. Propanc and any third-party manufacturers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.

 

With respect to post-market product advertising and promotion, the FDA imposes complex regulations on entities that advertise and promote pharmaceuticals, which include, among others, standards for direct-to-consumer advertising, promoting products for uses or in patient populations that are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors and civil or criminal penalties. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses.

 

Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. A NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing a NDA.

 

Adverse event reporting and submission of periodic reports is required following FDA approval of a NDA. The FDA also may require post-marketing testing, known as Phase IV testing, risk mitigation strategies and surveillance to monitor the effects of an approved product or to place conditions on an approval that could restrict the distribution or use of the product.

 

In June 2017, we were notified by the FDA that PRP had been granted orphan drug designation for the treatment of pancreatic cancer. Orphan drug designation may be granted by the FDA when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations. This qualifies us for various developmental incentives, including protocol assistance, the potential for research grants, the waiver of future application fees, and tax credits for clinical testing if we choose to host future clinical trials in the United States.

 

In October 2017, we submitted a request for a second orphan drug designation for PRP, this time for ovarian cancer.

 

On November 2, 2017, we were notified by the FDA that our request was not granted. The Office of Orphan Products Development (“OOPD”) stated that complete prevalence is used as a measure of disease in ovarian cancer, as this reflects the number of women who have been diagnosed with disease and may be eligible for treatment with the proposed therapy. Therefore, on the date of the submission of our application, the OOPD estimated that the prevalence of ovarian cancer was 228,110 cases. Since the prevalence exceeds the threshold of 200,000 to qualify for orphan drug designation, they could not grant our request. We may consider resubmitting our application if we can identify a suitable sub population in ovarian cancer, which may meet the target threshold.

 

European Union

 

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or market our product in those countries. The approval process varies from country to country and the time may differ than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Despite these differences, the clinical trials will be conducted according to international standards such as Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP), which is recognized by each foreign country under the International Conference of Harmonization (ICH) Guidelines. We will conduct our trials in each foreign jurisdiction according to these standards, undertaking a First-In-Human (FIH) Phase I study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics, and anti-tumor efficacy of PRP. This will be followed by two Phase II studies evaluating the efficacy and safety of PRP. To ensure harmonization between the jurisdictions, we intend to conduct regulatory meetings in the country where trials are conducted, as well as the FDA and European Medicines Agency. A pre-IND (Investigational New Drug) meeting will be held with the FDA once initial patient data has been collected from the FIH study to ensure acceptability of future planned Phase II trials.

 

Under European Union regulatory systems, we must submit and obtain authorization for a clinical trial application in each member state in which we intend to conduct a clinical trial. After we have completed clinical trials, we must obtain marketing authorization before it can market its product. We must submit applications for marketing authorizations for oncology products under a centralized procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The European Medicines Agency (the “EMA”) is the agency responsible for the scientific evaluation of medicines that are to be assessed via the centralized procedure.

 

On June 23, 2016, the UK government held a referendum to gauge voters’ support to remain or leave the European Union. The referendum resulted in 51.9% of UK voters in favor of leaving the European Union, commonly referred to as “Brexit.” On March 29, 2017, the UK invoked Article 50 of Lisbon Treaty to initiate complete withdrawal from the European Union, which was effectuated on January 31, 2020. The center for the EMA was based in London but the European Union has relocated the center to The Netherlands.

 

The impact of Brexit on the drug approval process in the UK is uncertain. Companies based in the UK and operating in the drug industry are urging the European Union and the UK to reach an agreement to harmonize the regulatory process once the UK officially exits the European Union.

 

 16 

 

 

Australia

 

In Australia, the relevant regulatory body responsible for the pharmaceutical industry is the Therapeutics Goods Administration (the “TGA”). Prescription medicines are regulated under the Therapeutic Goods Act 1989. Under the Therapeutic Goods Act, the Therapeutic Goods Administration evaluates new products for quality, safety and efficacy before being approved for market authorization, according to similar standards employed by the FDA and EMA in the United States and European Union, respectively. However, receiving market authorization in one or two regions does not guarantee approval in another.

 

Third-Party Payor Coverage and Reimbursement

 

Although none of our product candidates have been commercialized for any indication, if they are approved for marketing, commercial success of our product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state and private levels. In addition, in many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country.

 

Eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies.

 

In many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any foreign market.

 

The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. In the United States, recently passed legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.

 

Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.

 

Other Regulations

 

We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.

 

COMPETITION

 

The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our technology platforms, product candidates, know-how, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. The level of generic competition and the availability of reimbursement from government and other third-party payers will also significantly impact the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

 

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

 

 17 

 

 

EMPLOYEES

 

As of September 28, 2021, we have one full-time and one part-time employee. In addition to our employees, we engage key consultants and utilize the services of independent contractors to perform various services on our behalf. Some of our executive officers and directors are engaged in outside business activities that we do not believe conflict with our business. Over time, we may be required to hire additional employees or engage independent contractors to execute various projects that are necessary to grow and develop our business. These decisions will be made by our officers and directors, if and when appropriate.

 

CORPORATE INFORMATION

 

Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia. Our telephone number is 61 03 9882 0780. Our website is www.propanc.com. We can be contacted by email at www.propanc.com/contact. Our website’s information is not, and will not be deemed, a part of this Annual Report or incorporated into any other filings we make with the SEC.

 

AVAILABLE INFORMATION

 

Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents that we will file with or furnish to the SEC will be available free of charge by sending a written request to our Corporate Secretary at our corporate headquarters. Additionally, the documents we file with the SEC are or will be available free of charge at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Other information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The SEC’s website is www.sec.gov.

 

We maintain a corporate website at www.propanc.com. You will be able to access our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports, proxy statements and other information to be filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material will be electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this Annual Report.

 

ITEM 1A. RISK FACTORS

 

We are not required to provide this information as we are a smaller reporting company.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties.

 

Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia, which we lease from Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our Chief Executive Officer, Chief Financial Officer and a director, and his wife are owners and directors. The lease has a one-year term commencing May 6, 2021, and we are currently obligated to pay $3,606 AUD or $2,431 USD (depending on exchange rate), inclusive of tax, in rent per month.

 

Item 3. Legal Proceedings.

 

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or our subsidiary, threatened against or affecting our Company, our common stock, our subsidiary or of our companies or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

IRS Liability

 

As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the accrued expenses and other payable figure in the balance sheet. The Company recorded the penalties for all three years during the year ended June 30, 2018 and is negotiating a payment plan. The Company is current on all subsequent filings.

 

 18 

 

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock is quoted under the ticker symbol “PPCB” on the OTCQB. Only a limited market exists for our common stock. There is no assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a stockholder may be unable to resell his securities in our Company.

 

On September 24, 2021, the last reported sales price per share of our common stock on the OTCQB was $0.0249.

 

Security Holders

 

As of September 21, 2021, we had 76 record holders of our common stock.

 

Dividends

 

We have not paid any cash dividends to our stockholders. The declaration of any future cash dividends is at the discretion of our Board and depends upon our earnings, if any, our capital requirements and financial position, and general economic conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

 

Recent Sales of Unregistered Securities

 

Shares issued for conversion of convertible debt

 

During the year ended June 30, 2021, the Company issued an aggregate of 8,786,113 shares of its common stock at an average contractual conversion price of $0.13, ranging from $0.03 to $2.00, as a result of the conversion of principal of $1,018,867, interest of $103,321 and conversion fees $16,500 underlying certain outstanding convertible notes converted during such period.

 

There were 24,427 unissued shares which were considered issuable for accounting purposes during the first quarter of fiscal 2021 related to conversion notices dated and received in September 2020. In November 2020, the Company was notified by the note holder of the cancellation of these conversion notices and as such the Company reversed the effects of these transactions.

 

The Company has 197,308,116 shares of its common stock reserved for future issuances based on lender reserve requirements pursuant to underlying financing agreements at June 30, 2021.

 

Shares issued for services

 

On March 22, 2021, the Company issued an aggregate of 225,037 shares of the Company’s common stock to a consultant for services rendered from January 1, 2021 to March 22, 2021. The Company issued 225,037 shares of the Company’s common stock valued at $0.30 per share, being the closing price of the stock on the date of grant to such consultant, or $67,511.

 

 19 

 

 

Between March 2021 and June 2021, the Company issued an aggregate of 580,609 shares of the Company’s common stock to a consultant for services rendered from April 1, 2021 to June 30, 2021. The Company issued 580,609 shares of the Company’s common stock valued at $0.10 per share, being the closing price of the stock on the date of grant to such consultant, or $58,061.

 

Shares issued for exercise of warrants

 

During the year ended June 30, 2021, the Company received aggregate gross proceeds of $776,044 from the exercise of 10,445 prefunded warrants and 19,375 Series B Warrants resulting in the issuance of 29,820 shares of common stock. Additionally, the Company issued 4,199,979 shares of common stock from the alternate cashless exercise of 20 Series A and 1 Series C warrants.

 

Item 6. Selected Financial Data.

 

Not applicable to smaller reporting companies.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our business and results of operations in conjunction with the information set forth in our consolidated financial statements and notes thereto appearing under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. See “Forward-Looking Statements” on page 3 of this Annual Report. As used herein, references to the “Company,” “Propanc,” “we,” “our,” and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated.

 

U.S. Dollars are denoted herein by “USD,” “$” and “dollars”.

 

COVID-19

 

At Propanc, our highest priority remains the safety, health and well-being of our employees, their families and our communities. The COVID-19 pandemic is a highly fluid situation and it is not currently possible for us to reasonably estimate the impact it may have on our financial and operating results. We will continue to evaluate the impact of the COVID-19 pandemic on our business as we learn more and the impact of COVID-19 on our industry becomes clearer. We are complying health guidelines regarding safety procedures, including, but are not limited to, social distancing, remote working, and teleconferencing. The extent of the future impact of the COVID-19 pandemic on our business is uncertain and difficult to predict. Adverse global economic and market conditions as a result of COVID-19 could also adversely affect our business. If the pandemic continues to cause significant negative impacts to economic conditions, our results of operations, financial condition and liquidity could be adversely impacted.

 

Overview

 

We were incorporated in the state of Delaware as Propanc Health Group Corporation on November 23, 2010. In January 2011, to reorganize our Company, we acquired all of the outstanding shares of Propanc PTY LTD, an Australian corporation, on a one-for-one basis and Propanc PTY LTD became our wholly-owned subsidiary. Effective April 20, 2017, we changed our name to “Propanc Biopharma, Inc.” to better reflect our current stage of operations and development.

 

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

 

Recent Developments

 

On October 1, 2020, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 Euros ($35,145 USD) which shall be paid in four installment payments of 5,000 Euros in November 2020, 5,000 Euros ($5,858) in March 2021, 10,000 Euros ($11,715) in December 2021 and 10,000 Euros ($11,715) in September 2022. Additionally, the University shall hire and train a doctoral student for this project and as such the Company shall pay the University 25,837 Euros ($30,268 USD). In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of net revenues to the University.

 

On November 17, 2020, the Company effected a one-for-one thousand (1:1,000) reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”). Proportional adjustments for the Reverse Stock Split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements and in this annual report to reflect the Reverse Stock Split.

 

On May 11, 2021, the Company’s scientific researchers with the Universities of Jaén and Granada, published data in a peer reviewed journal, Expert Opinion on Biological Therapy, confirming the anti-tumor potential of a mixture of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Treatment with proenzymes sensitizes cancer stem cells which may allow standard treatment approaches like chemotherapy and radiotherapy to be more effective.

 

Between August 6, 2020 to June 29, 2021, advancements were made with the Company’s patent portfolio including allowed claims describing a pharmaceutical composition for treating cancer in Brazil (covering the Company’s lead patent application), a first granted patent describing a method to treat cancer stem cells in Australia, and granted patents in Australia and Indonesia, with allowed claims in Singapore, citing higher doses of a pharmaceutical composition. The advancements represent three of four patent families covering the Company’s lead product, PRP.

 

 20 

 

 

Results of Operations

 

The following discussion should be read in conjunction with the Company’s consolidated financial statements and notes thereto included elsewhere in this Report. The results discussed below are of the Company and its wholly-owned Australian subsidiary, Propanc PTY LTD.

 

Fiscal Year Ended June 30, 2021, as compared to the Fiscal Year Ended June 30, 2020

 

Revenue

 

For the fiscal years 2021 and 2020 we generated no revenue because we are currently undertaking research and development activities for market approval and no sales were generated in this period.

 

Administration Expense

 

Administration expense decreased to $1,553,075 for the year ended June 30, 2021 as compared to $3,281,464 for the year ended June 30, 2020. This decrease of approximately $1,728,000 is primarily attributable to a decrease of approximately $1,190,000 in stock-based expenses for services, decrease of approximately $128,000 of indirect capital raising costs, decrease in general consulting, legal, and investor relation fees of approximately $265,000, decrease in accounting fees of approximately $17,000, decrease in insurance expense of approximately $75,000, decrease of approximately $124,000 in marketing and market research expense, decrease in travel expenses of approximately $28,000, decrease of approximately $19,000 of other general and administrative expenses and offset by increase of approximately $118,000 in employee remuneration expense.

 

Occupancy Expense

 

Occupancy expense decreased by approximately $4,700 to $28,112 for the year ended June 30, 2021. The decrease primarily relates to exchange rate movements over the period when compared to the same period in 2020.

 

Research and Development Expenses

 

Research and development expenses were $230,956 for the year ended June 30, 2021, as compared to $179,987 for the year ended June 30, 2020. The increase in research and development expenses is primarily attributable to the two-year collaboration agreement with University Jaén which was executed in October 2020 to provide certain research services to the Company.

 

Interest Expense/Income

 

Interest expense decreased to $449,457 for the year ended June 30, 2021, as compared to $1,748,381 for the year ended June 30, 2020. Interest expense is primarily comprised of approximately $337,000 of debt discount amortization and accretion of put premium for the year ended June 30, 2021, and interest expense from conversion fees, prepayment penalty fees and accrual of interest expense for a total of approximately $113,000 for the year ended June 30, 2021.

 

This decrease of $1,298,924 is primarily attributable to a decrease in the issuance of convertible notes and was further reduced due to the conversion and repayment of convertible notes during the year ended June 30, 2021 which resulted to a decrease in accretion of put premium of approximately $636,000 during the year ended June 30, 2021, and the decrease in amortization of debt discount of approximately $598,000 during the year ended June 30, 2021. Additionally, interest expense from prepayment penalty fees decreased by approximately $99,000 offset by increase in conversion fees and accrual of interest expense for a total of $34,000 during the year ended June 30, 2021.

 

Change in Fair Value of Derivative Liabilities

 

Change in fair value of derivative liabilities changed by $393,479, to a loss of $8,186 for the year ended June 30, 2021, as compared to a gain of $385,293 for the year ended June 30, 2020. This change is primarily attributable to a decrease in the principal amount of convertible notes with bifurcated embedded conversion option derivatives during the year ended June 30, 2021.

 

Gain from Settlement of Debt, net

 

During the year ended June 30, 2021, the Company recorded gain from settlement of debt, net of $49,319 relating to two transactions. On March 22, 2021, the Company entered into a settlement agreement with our former counsel, Foley Shechter, whereby both parties agreed to settle all claims for professional fees owed for a total of $51,057. The Company paid the settlement amount of $51,057 on March 22, 2021. Prior to the settlement agreement, the Company recorded total accounts payable and accrued expenses $143,614. Accordingly, the Company recognized gain from settlement of debt of $92,557 during the year ended June 30, 2021.

 

Additionally, on March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement with Regal whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note for a total of $100,000. All other terms of the August 10, 2017 Convertible Note shall remain in full force and effect. Both parties agree that all future penalties under this note are waived unless the Company fails to authorize to distribute the requested shares upon conversion. The Company has the right to pay off the balance of any remaining amounts dues under this note in cash at any time more than 60 days after March 15, 2021. Prior to the Settlement Agreement, the Company recorded total liabilities $56,762 consisting of remaining principal amount of $8,500, accrued interest of $23,262 and accrued expenses of $25,000. Accordingly, the Company recognized loss from settlement of debt of $43,238 during the year ended June 30, 2021.

 

 21 

 

 

Gain (loss) on Extinguishment of Debt, net

 

During the year ended June 30, 2020, notes with principal amounts totaling $254,500 and accrued interest of $15,408 contained bifurcated embedded conversion option derivatives. Accordingly, the fair market value of the shares issued was $565,746 resulting in a loss on extinguishment at the time of conversion of $295,838 and $362,961 of derivative fair value was recorded as a gain on extinguishment at the time of conversion.

 

During the year ended June 30, 2021, notes with principal amounts totaling $95,000 and accrued interest of $3,000 contained bifurcated embedded conversion option derivatives. Accordingly, the fair market value of the shares issued was $178,368 resulting in a loss on extinguishment at the time of conversion of $80,368 and $130,975 of derivative fair value was recorded as a gain on extinguishment at the time of conversion, resulting in a net gain of $50,607.

 

Foreign Currency Transaction Gain (Loss)

 

Foreign currency transaction changed to a gain of $30,497 for the year ended June 30, 2021 as compared with a loss of $143,808 for the year ended June 30, 2020.

 

The foreign currency transaction decreased to a gain is partially attributable to the increase in exchange rates during the year ended June 30 2021, as compared to the year ended June 30, 2020.

 

Benefit (provision) for taxes

 

During the year ended June 30, 2021 and 2020, the Company applied for and received from the Australian Taxation Office a research and development tax credit in the amount of $113,415 and $134,728, respectively.

 

Net loss

 

Net loss decreased to $2,025,947 for the year ended June 30, 2021 as compared to a net loss of $4,740,723 for the year ended June 30, 2020. The change relates to the factors discussed above.

 

Deemed dividend

 

The Company recognized the value of the effect of a down round feature related to our Series A and C warrants when triggered. Upon the occurrence of the triggering event that resulted in a reduction of the strike price, the Company measured the value of the effect of the feature as the difference between the fair value of the warrants without the down round feature or before the strike price reduction and the fair value of the warrants with a strike price corresponding to the reduced strike price upon the down round feature being triggered. Accordingly, the Company recognized deemed dividend of $391,749 and a corresponding reduction of income available to common stockholders upon the alternate cashless exercise of these warrants.

 

Net loss available to common stockholders

 

Net loss available to common stockholders decreased to $2,417,696 for the year ended June 30, 2021 as compared to a net loss of $4,740,723 for the year ended June 30, 2020. The change relates to the factors discussed above.

 

Liquidity and Capital Resources

 

Current Financial Condition

 

As of June 30, 2021, we had total assets of $13,101, comprised primarily of cash of $2,255, GST tax receivable of $4,341, property and equipment, net, of $4,255 and security deposit of $2,250. As compared to June 30, 2020, we had total assets of $98,518, comprised primarily of cash of $67,007, GST tax receivable of $2,015, property and equipment, net, of $5,747 and operating lease right of use asset, net, $21,682.

 

We had current liabilities of $3,080,674, primarily comprised of net convertible debt of $624,583, accounts payable and accrued expenses of $1,894,486, employee benefit liability of $418,538, and embedded conversion option liabilities of $54,220 as of June 30, 2021. As compared to June 30, 2020, we had current liabilities of $3,739,943, primarily comprised of net convertible debt of $1,557,734, accounts payable and accrued expenses of $1,544,387, employee benefit liability of $354,109, and embedded conversion option liabilities of $354,109.

 

We have funded our operations primarily through the issuance of equity and/or convertible securities for cash. The cash was used primarily for payments for research and development, administration expenses, occupancy expenses, professional fees, consultants and travel.

 

During the year ended June 30, 2021 we received proceeds from exercise of warrants of $776,044 and proceeds from issuance of convertible notes of $325,000.

 

We have substantial capital resource requirements and have incurred significant losses since inception. As of June 30, 2021, we had $2,255 in cash. We depend upon debt and/or equity financing to fund our ongoing operations and to execute our current business plan. Such capital requirements are in excess of what we have in available cash and for which we currently have commitments. Therefore, we presently do not have enough available cash to meet our obligations over the next 12 months. If continued funding and capital resources are unavailable at reasonable terms, we may curtail our plan of operations. We will be required to obtain alternative or additional financing from financial institutions, investors or otherwise, in order to maintain and expand our existing operations. The failure by us to obtain such financing would have a material adverse effect upon our business, financial condition and results of operations, and adversely affecting our ability to complete ongoing activities in connection with our research and development programs.

 

Sources and Uses of Cash

 

   For the years ended June 30, 
   2021   2020 
Net cash used in operating activities   $(1,145,264)  $(1,849,589)
Net cash provided by financing activities   $1,058,044   $1,890,240 
Effect of exchange rate changes on cash   $22,468   $23,962 

 

 22 

 

 

Net Cash Flow from Operating Activities

 

Net cash used in operating activities was $1,145,264 for the year ended June 30, 2021, due to our net loss of $2,025,947, offset primarily by non-cash charges of amortization of debt discount of $136,527, stock-based compensation of $208,444, non-cash interest expense of $16,500, accretion of put premium of $200,410, change in fair value of derivatives of $8,186 addback foreign currency transaction gain of $30,497, gain from settlement of debt of $48,390 and $50,607 gain on extinguishment of debt. Net changes in operating assets and liabilities totaled $92,277, which is primarily attributable to increase in accounts payable of $177,382, increase in accrued expenses and other payables of $152,861, employee benefit liability of $33,134, and accrued interest of $80,582.

 

Net cash used in operating activities was $1,849,589 for the year ended June 30, 2020, due to our net loss of $4,740,723 offset primarily by non-cash charges of amortization of debt discount of $734,130, stock-based compensation of $1,398,868, accretion of put premium of $836,724, non-cash interest expense of $15,000, foreign currency transaction loss of $143,808 addback gain on extinguishment of debt of $67,123 and $385,293 of change in fair value of derivatives. Net changes in operating assets and liabilities totaled $212,547, which is primarily attributable to decrease in prepaid expenses and other assets of $83,157, increase in employee benefit liability of $35,724, and accrued interest of $156,417 and offset by decrease in accounts payable of $29,737 and accrued expenses and other payables of $9,740.

 

Net Cash Flow from Financing Activities

 

Cash flows provided by financing activities for the year ended June 30, 2021 were $1,058,044 as compared to $1,890,240 for the year ended June 30, 2020. During the year ended June 30, 2021 we received proceeds from the exercise of warrants of $776,044 and proceeds from issuance of convertible notes of $325,000 offset by repayments of convertible notes of $43,000. During the year ended June 30, 2020, we received proceeds from the sale of convertible promissory notes of $1,465,250 and sale of common stock of $450,000, net of $25,010 in issue costs.

 

Effect of Exchange Rate

 

The effect of the exchange rate on cash resulted in a $22,468 positive adjustment to cash flows in the year ended June 30, 2021 as compared to an adjustment of $23,962 to cash flows in the year ended June 30, 2020. The reason for the fluctuation is due to the application of currency translation rates throughout the cash flow statement, the volume of transactions within each period and the daily fluctuation in exchange rates.

 

Critical Accounting Estimates

 

Below is a discussion of our more subjective accounting estimation processes for purposes of explaining (i) the methodology used in calculating the estimates, (ii) the inherent uncertainties pertaining to such estimates, and (iii) the possible effects of a significant variance in actual experience, from that of the estimate, on our financial condition. Estimates involve numerous assumptions that, if incorrect, could create a material adverse impact on the Company’s results of operations and financial condition.

 

Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this filing is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph.

 

Foreign Currency Translation and Comprehensive Income (Loss): The Company’s wholly owned subsidiary’s functional currency is the AUD. For financial reporting purposes, the Australian Dollar (“AUD”) has been translated into USD as the Company’s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss as other income (expense). Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of other comprehensive income.

 

Accounting for Income Taxes: We are governed by Australian and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. We follow ASC 740, “Accounting for Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

 

The Company adopted provisions of ASC 740, Sections 25 through 60, “Accounting for Uncertainty in Income Taxes.” These sections provide detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Tax positions must meet a “more-likely-than-not” recognition threshold at the effective date to be recognized upon the adoption of ASC 740 and in subsequent periods.

 

 23 

 

 

Accounting for Stock Based Compensation: We record stock-based compensation in accordance with ASC 718, “Stock Compensation” and Staff Accounting Bulletin No. 107 issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The statement also requires the recognition of compensation expense for the fair value of any unvested stock option awards outstanding at the date of adoption. We value any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

 

We account for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718.

 

Derivative Instruments: ASC 815, “Derivatives and Hedging,” establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion, or payoff, of debt, we record the fair value of the conversion shares, remove the fair value of the related derivative liability, remove any discounts and record a net gain or loss on debt extinguishment.

 

Convertible Notes with Variable Conversion Options: We have entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at or around a fixed discount to the price of the common stock at the time of conversion. We treat these convertible notes as stock settled debt under ASC 480 and measure the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion and record the put premium as accretion to interest expense.

 

Research and Development Tax Credits: We may apply for Research and Development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, we do not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If we have net income then we can receive the credit which reduces its income tax liability. If we have net losses, then we may still receive a cash payment for the credit, however, our net operating loss carry forwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt.

 

Leases: In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The updated guidance requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606. This guidance is effective for interim and annual reporting periods beginning after December 15, 2018. The Company adopted this guidance effective July 1, 2019.

 

On July 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.

 

Recent Accounting Pronouncements

 

Please see section captioned “Recent Accounting Pronouncements” in Note 1 to our consolidated financial statements included in this Annual Report for a discussion of recently issued and adopted accounting pronouncements.

 

Going Concern Qualification

 

The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2021, the Company had no revenues, had a net loss of $2,025,947 and had net cash used in operations of $1,145,264. Additionally, as of June 30, 2021, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $3,074,078, $3,067,573, and $58,199,466, respectively.

 

 24 

 

 

Our independent registered public accounting firm has included a “Going Concern Qualification” in their audit report for each of the fiscal years ended June 30, 2021 and 2020. In addition, we have negative working capital and convertible debt that is past maturity that we are currently negotiating with lenders in order to amend the maturity dates. The foregoing raises substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. Our ability to continue as a going concern is dependent on our ability to execute our strategy and on our ability to raise additional funds and/or to consummate a public offering. Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity and/or convertible debt financing. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable to smaller reporting companies.

 

Item 8. Financial Statements and Supplementary Data.

 

The following audited consolidated financial statements of Propanc Biopharma, Inc. are included in this Annual Report:

 

 25 

 

 

PROPANC BIOPHARMA, INC.

INDEX TO FINANCIAL STATEMENTS

 

    Page
Audited Consolidated Financial Statements for the Fiscal Years Ended June 30, 2021 and 2020    
     
Report of Independent Registered Public Accounting Firm   F-2
     
Consolidated Balance Sheets as of June 30, 2021 and 2020   F-4
     
Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended June 30, 2021 and 2020   F-5
     
Consolidated Statements of Changes in Stockholders’ Deficit for the years ended June 30, 2021 and 2020   F-6
     
Consolidated Statements of Cash Flows for the years ended June 30, 2021 and 2020   F-7
     
Notes to Consolidated Financial Statements   F-8

 

F-1

 

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders’ and the Board of Directors of:

Propanc Biopharma, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets Propanc Biopharma, Inc. and Subsidiary (the “Company”) as of June 30, 2021 and 2020, the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ deficit, and cash flows, for each of the two years in the period ended June 30, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2021 and 2020, and the consolidated results of its operations and its cash flows for each of the two years in the period ended June 30, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has a net loss of $2,025,947 and net cash used in operating activities of $1,145,264 for the fiscal year ended June 30, 2021. The Company has a working capital deficit, stockholder’s deficit, and accumulated deficit of $3,074,078, $3,067,573, and $58,199,466 respectively, at June 30, 2021. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s Plan regarding these matters is also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

2295 NW Corporate Blvd., Suite 240 • Boca Raton, FL 33431-7328

Phone: (561) 995-8270 • Toll Free: (866) CPA-8500 • Fax: (561) 995-1920

www.salbergco.com • info@salbergco.com

Member National Association of Certified Valuation Analysts • Registered with the PCAOB

Member CPAConnect with Affiliated Offices Worldwide • Member AICPA Center for Audit Quality

 

F-2

 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Derivative Liabilities

 

As described in Footnote 12 “Derivative Financial Instruments and Fair Value Measurements” to the consolidated financial statements, the Company recorded derivative transactions that resulted primarily in a net derivative expense from change in fair value of conversion option liability of $8,186, and derivative liabilities of $54,220 at June 30, 2021.

 

We identified the evaluation of instruments and contracts to determine whether there are derivatives to be recorded, the analysis of the accounting treatment and presentation for derivative transactions and the valuation of derivatives as critical audit matters. Auditing management’s analysis of the above critical audit matters was complex and involved a high degree of subjectivity.

 

The primary procedures we performed to address these critical audit matters included (a) Reviewed and tested management’s conclusions as to whether certain instruments or contracts qualified for derivative treatment by comparing management’s analysis and conclusions to authoritative and interpretive literature, (b) Compared the accounting treatment and presentation to that described by the authoritative and interpretive literature, (c) Tested management’s process for valuing derivatives by comparing it to generally accepted methodologies for valuing derivatives, (d) Tested management’s valuation of the derivatives by testing assumptions and data used in the valuation model including the term, volatility and interest rate, and (e) Recomputed the derivative valuations.

 

/s/Salberg & Company, P.A.

 

SALBERG & COMPANY, P.A.

We have served as the Company’s auditor since 2011

Boca Raton, Florida

September 28, 2021

 

F-3

 

  

PROPANC BIOPHARMA, INC. AND SUBSIDIARY 

CONSOLIDATED BALANCE SHEETS

  

    June 30, 2021     June 30, 2020  
             
ASSETS                
                 
CURRENT ASSETS:                
Cash   $ 2,255     $ 67,007  
GST tax receivable     4,341       2,015  
                 
TOTAL CURRENT ASSETS     6,596       69,022  
                 
Security deposit - related party     2,250       2,067  
Operating lease right-of-use assets, net - related party     -       21,682  
Property and equipment, net     4,255       5,747  
                 
TOTAL ASSETS   $ 13,101     $ 98,518  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
                 
CURRENT LIABILITIES:                
Accounts payable   $ 1,002,335     $ 842,156  
Accrued expenses and other payables     892,151       702,231  
Convertible notes and related accrued interest, net of discounts and premiums     624,583       1,557,734  
Operating lease liability - related party     -       25,072  
Embedded conversion option liabilities     54,220       177,009  
Due to former director - related party     33,347       30,639  
Loan from former director - related party     55,500       50,993  
Employee benefit liability     418,538       354,109  
                 
TOTAL CURRENT LIABILITIES     3,080,674       3,739,943  
                 
TOTAL LIABILITIES   $ 3,080,674     $ 3,739,943  
                 
Commitments and Contingencies (See Note 9)     -           
                 
STOCKHOLDERS’ DEFICIT:                
Preferred stock, 1,500,005 shares authorized, $0.01 par value:                
Series A preferred stock, $0.01 par value; 500,000 shares authorized; 500,000 shares issued and outstanding as of June 30, 2021 and 2020   $ 5,000     $ 5,000  
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of June 30, 2021 and 2020     -       -  
Preferred stock value                
Common stock, $0.001 par value; 1,000,000,000 shares authorized;14,055,393 and 258,120 shares issued and outstanding as of June 30, 2021 and 2020, respectively     14,056       258  
Common stock issuable (59 and 0 shares as of June 30, 2021 and 2020, respectively)     -       -  
Additional paid-in capital     54,074,110       50,913,893  
Accumulated other comprehensive income     1,085,204       1,267,671  
Accumulated deficit     (58,199,466 )     (55,781,770 )
Treasury stock (1 share)     (46,477 )     (46,477 )
                 
TOTAL STOCKHOLDERS’ DEFICIT     (3,067,573 )     (3,641,425 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 13,101     $ 98,518  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

  

PROPANC BIOPHARMA, INC. AND SUBSIDIARY 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

  

    2021     2020  
    Years Ended June 30,  
    2021     2020  
             
REVENUE                
Revenue   $ -     $ -  
                 
OPERATING EXPENSES                
Administration expenses     1,553,075       3,281,464  
Occupancy expenses     28,112       32,809  
Research and development     230,956       179,987  
TOTAL OPERATING EXPENSES     1,812,143       3,494,260  
                 
LOSS FROM OPERATIONS     (1,812,143 )     (3,494,260 )
                 
OTHER INCOME (EXPENSE)                
Interest expense     (449,457 )     (1,748,381 )
Interest income     1       946  
Other income     -       57,636  
Change in fair value of derivative liabilities     (8,186 )     385,293  
Gain from settlement of debt, net     49,319       -  
Gain on extinguishment of debt, net     50,607       67,123  
Foreign currency transaction gain (loss)     30,497       (143,808 )
TOTAL OTHER EXPENSE, NET     (327,219 )     (1,381,191 )
                 
LOSS BEFORE TAXES     (2,139,362 )     (4,875,451 )
                 
Tax benefit     113,415       134,728  
                 
NET LOSS   (2,025,947 )   (4,740,723 )
                 
Deemed dividend    

(391,749

)     -   
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  

$

(2,417,696

)  

$

(4,740,723

)
                 
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS   $ (0.80 )   $ (192.45 )
                 
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING     3,032,612       24,634  
                 
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS   $ (2,417,696 )   $ (4,740,723 )
                 
OTHER COMPREHENSIVE INCOME (LOSS)                
Unrealized foreign currency translation gain (loss)     (182,467 )     200,673  
                 
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)     (182,467 )     200,673  
                 
TOTAL COMPREHENSIVE LOSS   $ (2,600,163 )   $ (4,540,050 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

  

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE YEARS ENDED JUNE 30, 2021 and 2020

 

    No. of Shares     Value     No. of Shares     Value     No. of Shares     Value     No. of Shares     Value     Capital     Deficit     Income     Stock     Deficit  
                Common                 Accumulated              
    Preferred Stock           Stock     Additional           Other           Total  
    Series A     Series B     Common Stock     Issuable     Paid-in     Accumulated     Comprehensive     Treasury     Stockholders'  
    No. of Shares     Value     No. of Shares     Value     No. of Shares     Value     No. of Shares     Value     Capital     Deficit     Income     Stock     Deficit  
                                                                               
                                                                               
Balance at June 30, 2019     500,000     $ 5,000       1     $ -       968     $ 1       -     $ -     $ 45,714,289     $ (51,041,047 )   $ 1,066,998     $ (46,477 )   $ (4,301,236 )
                                                                                                         
Issuance of common stock for cash     -       -       -       -       804       1       -       -       424,989       -       -       -       424,990  
                                                                                                         
Issuance of common stock for conversion of convertible debt and accrued interest     -       -       -       -       247,619       248       -       -       2,124,926       -       -       -       2,125,174